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Abstract
Abstract
Gene delivery tools play a key role in research and gene therapy. Since 1989, when the
first trial in humans took place, the improvement of transduction e ciency and safety
gained enormous attention to increase the therapy success.
In this context, the biotechnological aim of this thesis is to engineer three viral- and non-
viral delivery tools.
I developed a production and purification pipeline for in vivo grade recombinant adeno-
associated viruses (rAAVs) and established in vitro and ex vivo quality tests. By examina-
tion of the expression profiles of five rAAV serotypes on human cell lines and primary cells
of human, rodent and non-human primate origin, I can additionally provide a source which
enables the selection of the best-performing serotype for future applications. Additionally,
I generated a genetic toolbox for a straightforward expression construct generation, useful
for all three provided delivery tools.
Exosomes cannot only be used as biomarkers of diseases or as delivery tools for therapy,
but in combination with rAAVs, they are a powerful tool to enhance the AAVs‘ trans-
duction e ciency, and immunological safety. Here, we used the expertise in boosting the
exosome release by over-expression of the tetraspanin CD9, an exosomal marker-protein,
to engineer the production of exosome-associated AAVs (exo-AAVs), the second part of
my thesis. For the first time, we demonstrated that with this modification of producer
cells, exo-AAV production yields up to 32% more e cient viruses.
Lentiviruses, another well-established vector system in gene therapy, were introduced and
investigated to complete our gene delivery platform. Which is useful to unravel the mech-
anism behind the CD9‘s boosting e ect.
The third tool is represented by JC polyoma virus-derived virus-like particles (VLPs).
This quasi non-viral system is a promising tool for both research and clinical applications.
In order to increase the immunological safety of linear DNA delivery with the VLPs, we
adopted and investigated the utilisation of so-called MIDGE vectors, a monomolecular
linear DNA cassette, as cargo.
By attachment of targeting molecules to the outer surface of the VLPs, we could alter
the VLPs‘ tropism towards new target cells. Using this strategy, I aimed to develop a
retargeting towards nervous tissue which can by interchanging the targeting molecule also
be applied for lentiviruses and exo-AAVs.
In summary, these developments provide a handy way to improve the rAAVs‘ and exo-
AAVs‘ production, purification and quality assessment. In addition, we provide a platform
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for viral (rAAV, Lentivirus) and non-viral (VLP) gene delivery systems with interchange-
able expression features and cell-/tissue targeting opportunities.
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Since the first human trial in 1989, gene therapy has emerged as a revolutionary possibility
to treat or even cure genetic diseases and infectious disorders (Rosenberg et al., 1990).
In the following, I will provide a short introduction to the field of my biotechnological
thesis, with its scope to provide good delivery tools for gene therapy. For this purpose,
I will firstly introduce the field of gene therapy in general and also exemplify its specific
application in optogenetics.
Two viral vectors, recombinant adeno-associated viruses (rAAVs) and lentiviruses, will be
described in more detail, including the rather shortly known exosome-associated AAVs,
which represent the core tool in this thesis. Additionally, a virus-like particle technology
and its options of a re-targeted tropism are presented.
1.1 Gene therapy
Gene therapy is the transfer of genetic material with the scope to modify specific gene
functions of the receiving cell. Within this, three major modification routes can be clas-
sified: Gene augmentation for directed exogenous protein expression, gene correction and
gene-silencing or activation (Kay, 2011).
All these approaches have the need of an e cient and specific gene-delivery to the target
cells or tissues in common. The target can be reached by in vivo injection or ex vivo treat-
ment of cell explants with subsequent allogeneic or autologous transplantation (Figure 1).
The latter, for example, is successfully applied to hematopoietic stem cells (HSCs) which
are isolated from the blood or bone marrow. After a viral treatment that modifies their
gene expression, they are reposited by a systemic injection (Bi  et al., 2013; Aiuti et al.,
2013). Back in the organism, the engineered HSCs can cross the blood-brain barrier and
di erentiate into microglia-like cells, expressing the therapeutic construct. These cells,
for example, have been applied to treat X-linked adrenoleukodystrophy (X-ALD) that
express su cient amounts of the ALD protein after treatment (Aiuti et al., 2017; Cartier
et al., 2009).
Another promising approach is the correction of frameshift mutations to restore gene
functions. For example, transcription activator-like e ector nucleases (TALENs) driven
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approaches restore the dystrophin mutation that causes Duchenne muscular dystrophy
(Ousterout et al., 2013). RNA interference strategies showed in rodent models for Hunt-
ington´s disease the succesful downregulation of the mutant huntingtin gene and thereby
an inhibition of the disease causing protein aggregation (Franich et al., 2008; Stanek et al.,
2014).
sytemic 
local 
explant 
transplant 
MSC
Lentivirus 
AAV
in vivo ex vivo
systemic 
Figure 1: Application routes for gene therapy Delivery tools can be directly applied to the
organism´s target region or blood stream via injection. Alternatively, cell explants
can be treated ex vivo and re-implanted afterwards.
Researchers and clinicians use several strategies for the delivery of nucleotides, including
cationic liposome technologies or polycations, such as poly-l-lysine or polyethyleneimine
(San et al., 1993; Boussif et al., 1995). These methods use the formation of nanoparticles
incorporating the DNA or RNA. The cells are incubated with these complexes and incor-
porate them by the endosomal pathway. Another physical method is the electroporation,
in which an electrical field increases the permeability of the cell membrane and the uptake
of nucleotides. The latter is well-established for T-cell modification (Till et al., 2008; Zhao
et al., 2006; Van Tendeloo et al., 2000).
However, these methods have limitations, such as not transfecting specific cell types or
having a limited access to the brain. Furthermore, the targeted delivery to cell subpop-
ulations is also more complicated to achieve. Circumventing these just named issues,
20
1 Introduction
biological tools like viruses have a big potential. They can even deliver the transgene
through physical barriers like the blood-brain barrier or the inner limiting membrane of
the retina (Foust et al., 2009; Duque et al., 2009; Dalkara et al., 2009).
1.1.1 Viral vectors in gene therapy
The application of viral vectors in gene therapy is constantly increasing (Chapin and Mon-
ahan, 2017). A variety of them are used including adenoviruses, herpes simplex viruses,
lentiviruses, AAVs, and others (Crystal, 2014; Wold and Toth, 2013; Garrido et al., 1998;
Tomás et al., 2013; Hocquemiller et al., 2016).
The first virus-based gene therapy which was available on the European market is Glybera®,
an AAV-based treatment of the rare disease lipoprotein lipase (LPL) deficiency. The
lentivirus-based therapeutic called Stimvelis®, used to treat patients with adenosine deam-
inase severe combined immunodeficiency (ADA-SCID), can also be found in clinics (Aiuti
et al., 2017; Melchiorri et al., 2013).
Pre-clinical tests in large animal models are frequently under debate, as researchers are
underlining the importance of these tests before proceeding with humans. Of course, this
public debate is currently stressing the ethical concerns. Therefore, as far as possible, it
is important to test potential cures in adequate in vitro and ex vivo approaches before
testing them in living organisms.
But, however, in vitro and ex vivo test systems have the limitation that they just re-
construct a restricted part of the whole body and the in vivo e ciency and the required
viral load can only be roughly estimated. Especially for systemic injections, one can only
assume how the delivery tool will spread in the body and which o -targets will be trans-
duced. Nevertheless, numerous models help to reduce animal experiments, man power
and costs such as cerebral organoid models of the human brain, cultured human donor
retinal explants, iPS-derived human retinal organoids, models for the blood-brain barrier
or microfluidic organs-on-chips which are all therefore developed (Lancaster et al., 2013;
Orlans et al., 2018; Quinn et al., 2018; Garberg et al., 2005; Cho et al., 2015; Helms et al.,
2016; Bhatia and Ingber, 2014; Mewes et al., 2012).
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1.1.2 Optogenetics in research and for therapy
Optogenetics, as the name says, combines the genetic with an optic approach to modulate
the electrical activity of excitable cells (Figure 2). Its history began in 2004, with Pan,
Bodyden, and Deisseroth being able to control the neuronal activity of opsin expressing
cells in vitro by the stimulation with light for the first time (Boyden et al., 2005).
The genetic compounds of optogenetics are opsins, light-sensitive transmembrane proteins.
Under exposure to light of a certain wavelength they change their conformation which
results in an ion flow. Depending on the charge change, the cell is either depolarized
or hyperpolarized. An inward directed cation flow for example depolarizes the neuronal
membrane and triggers an action potential. The most frequently used opsins in early days
were Channelrhodpsin-2, Halorhodopsin and ArchT with a toolbox of new variations
allowing a red-shifted action spectrum or step-function to prolong the excitable state
nowadays (Nagel et al., 2003; Boyden et al., 2005; Han and Boyden, 2007; Han et al.,
2011; Gunaydin et al., 2010; Packer et al., 2012).
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current in both directions, and can be used
for inhibiting neuronal activity and control-
ling behavior with light [6] (Figure 1). How-
ever, more in-depth analyses of activity,
speed, and robustness of this synthetic
channel in different neuron types and in
awake, freely moving animals are needed
to prove its potential in comparison to light-
activated channels and pumps that are
currently used. Thus, a powerful natural
channel that transfers anions exclusively
would greatly help tomove the applications
of optogenetics forward.
A recent study by Govorunova, Spudich
and colleagues does just this. They
describe a family of light-gated anion
channels from cryptophyte algae they
named the Anion Channel Rhodopsins
(ACRs) [7]. These novel inhibiting channels
allow for light-dependent hyperpolariza-
tion and neuronal silencing, allowing pre-
cisely controlled optical silencing of neural
activity at high frequencies. They have
rapid kinetics, high-sensitivity and abso-
lute anion selectivity, which brings scien-
tists closer to having a fully developed
optogenetic toolkit to understand the
molecular mechanisms underlying neuro-
logical and neuropsychiatric disorders.
Along with this, development of more
effective optogenetic-based neurostimu-
lation will help to deepen our understand-
ing of arising psychiatric symptoms and
to ultimately aid in developing novel
treatments. However, despite extensive
research in rodents, worms and fruit ﬂies,
studies in nonhuman primates [8] are nec-
essary to understand themolecular mech-
anisms underlying neural computation
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Figure 1. Optogenetic [1_TD$DIFF]Control of Neuronal Firing in Mice Using Light-Gated Channels. Light of appropriate wavelengths is delivered in vivo through chronic
ﬁber implants to the brain cells expressing the light-gated channels. Natural light-activated channelrhodopsins allow for fast optical depolarization of neurons. Synthetic
and natural anion channels as well as synthetic LOV-based potassium channels induce optical hyperpolarization after light stimulation. This setup makes it possible to
control neurons with an unprecedented degree of spatial, temporal, and neurochemical precision.
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Figure 2: Optogenetic The ligh - o trol ed modulatio f cell ctivity uses he expression
of opsin . De endin n h induced ion-fl w they act as activator or silencer. With
permission from Kianianmomeni and Hallmann (2015).
Optogenetics is pplied in various fields o research and p tential clinical applications and
is not any more limited to neurons, but also the light-driven m dulatio of glia cells and
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the control of the cardiac function comparable to a pacemaker are present applications
(Pelluru et al., 2016; Arrenberg et al., 2010). Furthermore, the restoration of vision and
hearing are under investigation (Bourzac, 2016; Moser, 2015). It might be a direct way to
enable inner retinal cells to act as photoreceptors making them directly sensitive to light
(Cha ol et al., 2017; Kleinlogel, 2017). The optogenetic restoration of hearing is aiming
at an improved frequency and intensity resolution, compared to conventional prosthetic
cochlea implants for humans (Moser, 2015). Optogenetics finds its application in research
to functionally and structurally map the connections of brain regions, or investigating
the functions of sleep by the optogenetic modulation of the sleep behaviour in mice (Lim
et al., 2013; Rolls et al., 2011).
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1.2 Adeno-associated viruses
50 nm
Figure 3: Adeno-associated virus Negative
stained rAAV5 capsid in electron mi-
croscopy.
Adeno-associated viruses (AAVs) have
emerged as an important tool for research
and clinics (Figure 3). They have been
known since the 1960s when they were
discovered as contaminants of adenovirus
preparations, where they finally derived
their name from (Atchison et al., 1965;
Hoggan et al., 1966). They are about
25 nm small, non-enveloped viruses which
bear a single-strand genome that can either
be the minus- or the plus-strand (Hoggan
et al., 1966; Berns and Rose, 1970). AAV
is a member of the genus Dependoviruses,
replication deficient and leads to a latent
infection with no connected disease.
For its replication it requires another virus
that lyses the cell. This helper function can be provided by adenoviruses or herpesviruses
(Hoggan et al., 1972). A dozen of serotypes and a hundred variants have been isolated,
both di ering in their genome and in capsid protein structure (Wu et al., 2006).
The AAV genome is flanked by two palindromic internal repeats (ITRs), which are re-
quired for genome replication and packaging. They are the only cis-acting elements in the
viral vector. Consequently, the ITRs are the only viral sequences which are transferred to
the recipient cells. The ITRs of AAV2 are usually used to flank recombinant expression
constructs because they can be packed into capsids of di erent serotypes. Therefore, the
nomenclature of a chimeric rAAV with ITRs of AAV2 in a serotype 5 capsid is rAAV2/5.
However, to especially simplify labeling and when the result is based on the capsids, the
ITR serotype is not declared but only the capsid serotype. Furthermore, AAV2 is the
most studied wild-type virus, as mainly all molecular biology was undertaken with AAV2
in the first thirty years after its discovery and it was the first serotype to be developed
into a recombinant vector for transgene delivery (Carter, 2004).
Three proteins, VP1, VP2, and VP3, form the capsid with 60 subunits in a 1:1:10 stoi-
chiometry (Johnson et al., 1971). Each serotype has a characteristic tropism to specific
cell types or tissues, that depends on the binding of capsid proteins to membrane glyco-
sides.
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AAV5, for example, was described to use alpha-2,3-N-linked sialic acid with the platelet-
derived growth factor receptor as co-receptor (Walters et al., 2001; Kaludov et al., 2001).
In contrast, AAV1 and AAV6 facilitate binding through –-2,3- and –-2,6-N-linked sialic
acid (Wu et al., 2006). A recent discovery identified a type 1 transmembrane protein
mediating the cell entry of various serotypes. Now, this receptor is simply denoted as
AAVR. It facilitates a rapid endocytosis and the tra cking to the trans-Golgi network
(Pillay et al., 2016).
Additionally, in the case of in vivo injection, the AAVs tropism can vary depending on
the applied concentration, making it even more challenging to find the best serotype for
an application (Gerits et al., 2015; Taymans et al., 2007).
Whereas AAV2 is internalized via clathrin-coated pits (Bartlett et al., 2000), AAV5 en-
ters the cell through clathrin-coated vesicles. Passing the endocytic pathway, they subse-
quently use a phospholipase domain in the capsid to escape the endosome. The capsid is
then transported to the nucleus, the viral genome released and the host-cell DNA poly-
merase converts the single-stranded genome to a double stranded DNA (Fisher et al.,
1996; Ferrari et al., 1996). But the tra cking of the various serotypes and the delivery of
its DNA in the nucleus are still poorly understood.
Wild-type AAVs integrate within the site AAVS1 of the human chromosome 19 with a
high precision (Samulski et al., 1991; Kotin et al., 1990). Thereby the rep protein mediates
the site-specific integration. Integration occurs with a very low frequency using recombi-
nant AAVs, because they usually lack the rep protein sequence in their genome (McCarty
et al., 2004; Weitzman et al., 1994). The transferred expression construct mainly remains
extrachromosomal as duplexed, circular episomes (Gerry et al., 1973). In non-dividing
cells, the transgene expression can consequently persist for a sustained time, whereas it
is transient in dividing cells.
Besides its gene delivery for extrachromosomal persistence, AAVs can also be used for
gene-targeting. The single-stranded vector DNA serves as donor template for a homolog
recombination to correct the host cell genome (Russell and Hirata, 1998).
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Limitations of rAAVs for clinical approaches
The use of rAAVs, especially for clinics, still faces some hurdles which are mainly caused
by its:
• target specificity
• packaging limit
• good manufacturing process (GMP) production in high quantities
• immunology.
The following section will sum up these challenges including the current approaches to
solve them.
Target specificity - Numerous studies have been undertaken to elucidate the viral tropism
after systemic or local injection in small and large animal models (Gerits et al., 2015;
Taymans et al., 2007; Zincarelli et al., 2008). The outcome can highly vary depending on
the site of injection, the virus load, and the species. For example, numerous serotypes are
used to target brain structures. These findings indicate the lack of a common knowledge
about the most suitable serotype.
To tackle the hurdle of cell specificity, the serotypes are custom-designed via e.g. di-
rected evolution of the capsid structure or conjugate-based targeting by the incorporation
of high-a nity ligands into the latter (Wu et al., 2006; Yang et al., 2011; Ponnazhagan
et al., 2002).
Regarding the expression construct, promoters are used which are specifically active in the
target tissue or silenced in o -target tissues (Shevtsova et al., 2005; Geisler and Fechner,
2016). However, the constitutive CAG promotor is used in most expression constructs
for clinical trials tackling CNS diseases such as Parkinson (Piguet et al., 2017). One ap-
proach which is mainly applied in small animal models is the use of transgene lines that
stably express the cre-recombinase in specific tissues. After a widespread systemic rAAV
application and transduction of various cells, the transgene expression is only activated
in the cre-positive cells (Saunders et al., 2012).
Packaging limit - AAVs have a natural genome of approximately 4.7 kb in size, a limit also
considered for a transgene capacity. Packaging of larger constructs lead to fragmented
genome packaging and truncated protein expression (Wu et al., 2010). The so-called
dual-AAVs are used to transfer the coding sequence for attempts where bigger proteins
are required (McClements and MacLaren, 2017). For this, the formerly over-sized con-
struct is split into two, partly overlapping sequences and a mixed population of the two
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rAAVs is applied. In cells which received both viruses, the gene recombines within the
cell and facilitates the expression of the full-lengths protein. The full mechanism of how
the recombination works is still unknown and it requires, of course, a highly e cient
transduction of the cells with both viruses.
Furthermore, the double-strand synthesis is a rate-limiting step in transgene expression.
Scientists developed the self-complementary rAAVs (scAAV) to achieve a faster onset of
expression. The genome, flanked by ITRs, subsequently folds into a double-stand DNA
that is covalently linked on one end (McCarty et al., 2003). Without the need of the
second-strand synthesis in the cell, the expression of the gene can start earlier.
Production under GMP conditions - One of the biggest hurdles to make rAAV treatment
available for a broad population is the GMP conform production in high amounts. New
and modified production and purification protocols for rAAVs are constantly published
nearly every month.
Depending on the serotype, AAVs mainly retain in the packaging cell line or are secreted
into the media, leading to the need of di erent purification protocols (Vandenberghe et al.,
2010). The standard harvesting procedures require cell lysis and virus separation from cell
components and media by chromatographical methods or gradient centrifugation (Smith
et al., 2003; Strobel et al., 2015; Zolotukhin et al., 1999). The purification needs to be
adjusted to each serotype in particular and these facts demonstrate that not one gold
standard protocol has been identified yet. Due to the ine cient and di cult process of
scaling up rAAV production, it remains expensive, laborious and requires high experience
to obtain a good quality, high titer virus.
The titer, the concentration of an AAV sample, can be given in three variants:
• the genomic titer of vector genome copie concentration (vg/ml) determined by dot
blot or real-time PCR
• the capsid concentration determined by ELISA
• or the concentration of transducing units (TU/ml) that is determined by transduc-
tion assays.
Although the genomic titer is routinely used this can be problematic as it is comparably
and reproducably determined in the same laboratory but can vary between laborato-
ries. Additionally, depending on the purification method, the functionality of the viral
preparation shows enormous variation. A preparation with 4x1010 vg/ml and 75% un-
infective particles for expample has the same infective potential as a a preparation with
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2x1010 vg/ml but 50% uninfective particles. The important di erence is, that the latter
comes with a lower load of capsids, which could trigger an immune response.
Clinical trials apply titers ranging from 1010 vg in total to 1014 vg/kg body weight (Piguet
et al., 2017). Normally the sample concentrations are 1013 vg/ml, which then limits the
possible virus load if the injection volume is also limited like for example in the brain.
Immunology - AAVs cause a latent infection with a mild immune response that can be
cell-mediated or humoral (Mingozzi and High, 2013). Due to the lack of symptoms,
the infection rate of the whole population is unknown and the subsequent abundance of
neutralizing antibodies can only be diagnosed with an immunology test. The cytotoxic
T cell-mediated response seems to be induced by the serotype and the route of application
(Wang et al., 2007; Brockstedt et al., 1999).
The immune response is primarily humoral, mediated by neutralizing antibodies which
were found in several preclinical animal models and human subjects with, to give an
example, a prevalence of 59.5 % against AAV1 (Calcedo et al., 2015; Greenberg et al.,
2016). Additionally, depending on the serotype and geographical area, the existence of
antibodies vary. This factor dramatically reduces the transduction e ciency as well as
the possibility of a second injection of the same serotype. To circumvent this hurdle both
scientists and clinicians, check before the treatment whether the first choice serotype can
be applied or whether an alternative one has to be administered. As well as for the
serotype specificity, there is ongoing research for bioengineered capsids that will not be
recognised by the antibodies (Paulk et al., 2017). Furthermore, exosome-associated AAVs
are a variant of rAAVs, that overcome this hurdle, as described in the following section.
1.2.1 Exosome-associated AAVs
Numerous cell types of mammals, bacteria, plants and fungi release membraneous com-
partments from originally either intraluminal or plasma membranes into the surrounding
milieu (Yoon et al., 2014; Blenkiron et al., 2016; Wang et al., 2013b; Jo e et al., 2016).
These extracellular vesicles with 30-2,000 nm in diameter are classified depending on their
size, with exosomes being 30-100 nm in diameter (Yoon et al., 2014; Théry et al., 2002).
Additionally, they can be identified by some enriched proteins. These so-called exosomal
marker proteins include the transmembrane tetraspanin CD9 (Hemler, 2005). Exosomes
contain nucleic acids and proteins and act as message carriers between cells (Théry et al.,
2002; Chiba et al., 2012; Cheng et al., 2014; Kalluri and LeBleu, 2016).
Within their first publication in 2012, Maquire et al. described a population of rAAVs
28
1 Introduction
that were associated with extracellular vesicles (Figure 4). These, later called exosome-
associated AAVs (exo-AAVs), have some functional advantages over the free rAAVs which
will be described below (Maguire et al., 2012). Electron microscopy indicates that the
rAAVs are located both inside the vesicle as well as attached to its surface (György et al.,
2017; Fitzpatrick et al., 2014). Nevertheless, it still has to be elucidated how they enter
or attach to the exosomes and whether this happens within or outside of the cell.
However, in our hands, cochleostomy results were more variable and
there were more instances with very low GFP expression.
Because GFP expression in individual hair cells may vary with multi-
ple AAV genomes being delivered, we quantiﬁed GFP intensity using
automated image analysis. Among GFP-positive IHCs, average GFP
ﬂuorescence intensity per cell was 70% higher with exo-AAV than
with conventional AAV, with either cochleostomy or RWM injection
(p < 0.01 for cochleostomy and p < 0.05 for RWM injection; Fig-
ure 2C). For OHCs, no signiﬁcant difference in GFP intensity per
cell was evident between exo-AAV1 and conventional AAV1.
For cochleostomy, transduction rates varied with distance from the
injection site. We counted more transduced hair cells in the base
(near the injection site) than in the apex (Figure 2D). The gradient
was particularly steep and signiﬁcant for OHCs, with only a few
OHCs transduced at the apex (repeated-measures ANOVA for the
entire dataset to analyze the relationship between location and trans-
duction; p = 0.0009 for AAV1 and p = 0.02 for exo-AAV1). With
RWM injection, however, there was no signiﬁcant gradient, suggest-
ing that the virus can diffuse more freely with this approach. Overall,
in all subregions tested, with both injection routes, exo-AAV1 signif-
icantly outperformed conventional AAV1 (Figure 2D).
With cochleostomy injections of either conventional or exo-AAV1,
we also observed robust expression of GFP in spiral ganglion neurons,
cells in the inner sulcus, Claudius cells, and Hensen cells (Figure S3).
Surprisingly, GFP-positive hair cells were also evident in the utricle
and in the ampullas of the lateral semicircular canals following
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Figure 1. Exo-AAV Outperforms Conventional AAV in Hair Cell Transduction in Culture
(A) Standard (conventional) AAV and exo-AAV production workflow. AAV was purified from HEK293T cell lysate, whereas exo-AAV was isolated from the culture medium of
the cells. Cryoelectron microscopy shows AAV1 capsids associated with exosomes. White arrowheads show AAV capsids, whereas the black arrowhead indicates the lipid
membrane. Scale bars, 50 nm. (B) Transduction of cochlear whole mount cultures with AAV1-CBA-GFP or exo-AAV1-CBA-GFP. Cochleas were explanted fromCD1mice at
P1. Vectors were added (1011 GCs) the following day and incubated overnight. Organs were cultured for 3 more days. Exo-AAV1-GFP shows efficient transduction of IHCs
and OHCs. Hair cells were labeled with anti-myosin VIIa antibody. Scale bar, 20 mm. (C) Proportion of GFP-positive hair cells in cochleas transduced with 1 ! 1011 GCs of
conventional AAV1 or exo-AAV1. Numbers in the bars represent the number of cochleas. Three images were taken for each cochlea (base, middle, and apex; fields chosen
by distance). Mean ± SEM; ***p < 0.001, **p < 0.01, one-tailed t test. (D) Proportion of GFP-positive hair cells in different regions of the cochlea (basal, middle, and apical
turns) transduced with conventional AAV1 or exo-AAV1. n = 6 cochleas for each data point; **p < 0.01, one-tailed t test. Mean ± SEM. (E) GFP-positive hair cells in cochleas
transduced with 1 ! 1011 GCs of conventional AAV9 or exo-AAV9. Mean ± SEM; ***p < 0.001, *p < 0.05, one-tailed t test.
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Figure 4: Exosome-associated AAVs Har-
vesting procedure of standard rAAVs
and exo-AAV. Standard rAAV1 cap-
sids are not associated with vesicles
whereas this is clear for exo-AAVs.
AAV capsids are marked with white
arrowheads, whereas the lipid mem-
brane is marked with the black ar-
rowhead. Scale bar equals 50 nm.
Creative commons license CC BY-
NC-ND 4.0 (György et al., 2017).
Exo-AAVs have the potential to improve
gene transfer via rAAVs. For example, exo-
AAVs of several serotypes are more e -
cient in transduction of cell culture and
they presumably shield the rAAV vector
against anti-AAV antibodies and increase
its resistance (Maguire et al., 2012; György
et al., 2014; Meliani et al., 2017). These
beneficial features of exo-AAVs have also
been proven by in vivo studies. Exo-
AAVs pass through the blood-brain barrier
and the inner limiting membrane of the
retina more e ciently compared to their
free counterpart (Hudry et al., 2016; Wass-
mer et al., 2017). Moreover, exo-AAV9 and
exo-AAV8 are more e cient in transduc-
tion of the CNS than their free rAAV coun-
terpart (Hudry et al., 2016).
In contrast to free AAVs, exo-AAVs are
harvested from the media by a sequential
centrifugation with the final sample be-
ing recovered from the 100 k x g pellet
(Hudry et al., 2016). In this process, all
cell-derived components which pellet in the
20 k x g centrifugation step are removed, as
well as components that did not sediment
at all. In contrast to the standard rAAV
purification protocols aiming at a
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maximum pure sample, the exo-AAVs are rather impure, including undetermined supple-
ments which might influence its transduction behavior as well. Similar to e.g. lentiviruses,
exo-AAVs can be retargeted. For this purpose, the targeting-peptide like VSV-G is inte-
grated in the lipid membrane of the exosome (Maguire et al., 2012; György et al., 2014).
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1.3 Lentiviruses
Lentiviruses are pathogens of animals and humans which cause a persistent infection with
symptoms appearing after several months or years (Campbell and Robinson, 1998).
Lentiviral vectors for research and gene therapy are usually derived from the equine in-
fectious anemia virus (EIAV), the siam (SIV), the feline (FIV), or the human immunod-
eficiency virus (HIV-1) (Wong et al., 2004; Kobayashi et al., 2003; Saenz et al., 2012; Liu
and Berkhout, 2014).
Lentiviruses are single-stranded RNA viruses and, in contrast to AAVs, obtain a host-
derived double lipid membrane envelope that they acquire upon budding from the cell
membrane (Adamson and Jones, 2004). The envelope contains specific cellular receptors
for the binding and final fusion with the cell membrane. Thereby, the viral core is released
into the cell, disintegrates and its RNA genome is reverse transcribed into double-stranded
cDNA. An active transport guides the viral DNA in the nucleus where it integrates into
the host genome with the help of the virus-derived integrase (Bukrinsky et al., 1993).
Therefore, lentiviruses have the ability to transfect dividing and non-dividing cells like
neurons and stably express the transgene (Naldini et al., 1996).
Its natural genome is flanked by two long terminal repeats (LTRs) and harbors the genes
for regulatory and accessory proteins. Furthermore it contains the enzymatic and struc-
tural genes env, pol, and also gag which codes for the envelope glycoproteins that interact
with the host cell membrane, replication enzymes and the viral core, respectively. The
LTRs have embedded the polyadenylation signal, promotor, and enhancer sequences that
are important for viral gene expression and virus integration (Buchschacher and Wong-
Staal, 2000).
Lentiviruses as research tools
In this study, we produced replication deficient HIV-1-based lentiviruses of the second
generation that uses the co-transfection of a three plasmid system (Gruber et al., 2000;
Zu erey et al., 1998). This system improves the safety of the production and application
by avoiding the generation of replicative viruses because the viral genes are distributed
on di erent plasmids. The cells are transfected with a packaging plasmids which codes
for gag, pol, and rev, a plasmid that codes for the envelope proteins and the transfer vec-
tor which contains the expression cassette with the transgene flanked by the LTRs (Kim
et al., 1998).
The capsid assembles in the cell and internalises the reverse transcribed expression cas-
sette. The envelope proteins are synthesized by the cell and embedded in its plasma
membrane. Exiting the cell by budding from the plasma membrane, the viral envelope
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contains a mixture of its proteins. Finally, the virus can be harvested from the condi-
tioned cell culture media and subsequently directly applied or further purified (Coleman
et al., 2003).
It is possible to alter the viral tropism by pseudotyping, i.e. to exchange the viral envelope
proteins with other viral glycoproteins as previously mentioned for the exo-AAVs. For
example, VSV-G from the vesicular stomatitis virus can be used to broaden the tropism
and also the rabies virus glycoprotein (RVG) can be integrated to shift the tropism to
the acetylcholine receptor (Burns et al., 1993; Mochizuki et al., 1998; Lentz, 1990). Ad-
ditionally, engineered proteins like single chain antibodies can be integrated and exposed
on the envelope (Friedel et al., 2015).
Lentiviruses have an advantage and disadvantage at the same time, namely being able
to integrate into the host cell chromosomes. On the one hand, the transgene is stably
expressed as long as the promotor is not silenced and the transduced cells are alive. On
the other hand, however, the integration can lead to gene damages and bears an oncogenic
potential (Schlimgen et al., 2016). To avoid negative e ects, researchers have developed
non-integrative lentiviruses that have a mutated integrase. All the valuable features, in-
cluding highly e cient transduction of almost every cell type and the ease of production
are maintained, but the expression cassette remains in an episomal viral form (Naldini
and Verma, 2000; Delenda, 2004; Banasik and McCray, 2010). Due to their e ective
transduction and long-term expression even in the in non-human primates´ cortex and
also because of their easy production in research laboratories, lentiviruses have become a
powerful tool for neuro-optogentic experiments. But, compared to the more stable AAVs
which lack a membraneous envelope, the lentiviruses´ lifetime is rather short, due to their
rather fragile envelope (Han, 2012).
The first human clinical trial with lentiviruses was performed in 2003 with the objective to
treat HIV infection with an antisense RNA expression against its envelope glycoproteins
(Levine et al., 2006). Since then, an increasing number of clinical trials with lentiviruses
for a wide range of human diseases have been performed. Thereby, the virus is used
in a direct injection or for treatment of hematopoietic stem cells, including treatments
for Parkinson´s disease, Wiscott-Aldrich syndrome and X-linked adrenoleukodystrophy
(ALD) (Palfi et al., 2014; Aiuti et al., 2013; Cartier et al., 2009).
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1.4 JC Polyoma virus derived virus-like particles
Virus-like particles (VLP) are virus particles that only consist of the viral capsid pro-
teins and lack any viral nucleic acids. Many viruses have been used to generate these
non-infectious VLPs, as the human papillomavirus and the murine or human JC poly-
omavirus (Kirnbauer et al., 1992; Tegerstedt et al., 2005; Salunke et al., 1986).
The human JC Polyoma Virus (JCV) was first isolated and cultured from a patient with
progressive multifocal leukoencephalopathy. The patient´s name was John Cuningham,
whose initials were used to name the virus (Padgett et al., 1971). JCV has a broad preva-
lence in the human population, with over 50 % having a silent infection (Olsson et al.,
2013). The latent infection can give rise to progressive multifocal leukoencephalopathy
(PML) in immunosuppressed individuals, caused by the infection and later result in fatal
lytic destruction of astrocytes and oligodendrocytes (Ferenczy et al., 2012).
The native virus genome is a 5.1 kb double-stranded circular DNA molecule that is asso-
ciated with histone core proteins derived from the host cell in a chromatin-like complex
(Frisque et al., 1984; Wollebo et al., 2013). It is encapsulated in a non-enveloped, icosahe-
dral protein capsid of 40.5-44 nm in diameter, composed of the three structural proteins
VP1, VP2, and VP3 (Eash et al., 2006; Frisque et al., 1984; Goldmann et al., 1999). VP1
is a 42 kDa protein and is the main capsid component with about 80 % (Gillock et al.,
1997). It alone forms pentamers and is able to form the outer capsid with 72 of these
sub-units linked by its flexible, C-terminal arm (Salunke et al., 1986; Ou et al., 1999).
The Ca2+ binding domains within the pentamers and the disulphide bonds between the
pentamers stabilise the VP1 interactions (Chen et al., 2001). A DNA binding domain
on VP1, that is not sequence specific, e ectuates the encapsulation of the viral DNA
(Moreland et al., 1991; Ou et al., 1999).
JCVs natural tropism is defined through its binding domains on the VP1 capsid sur-
face. For an infection, the virus firstly attaches to the exposed –-2,6-linked sialic acid
on a lactoseries tetrasaccharide c (LSTc) glycan and secondly to the serotonin receptors
5-HT2a-c (Liu et al., 1998; Komagome et al., 2002; Elphick et al., 2004; Neu et al., 2010).
A ligand-inducible clathrin-dependent endocytosis leads to the cell-entry and subsequent
tra cking to the ER with the initial uncoating of the virion (Pho et al., 2000; Querbes
et al., 2004, 2006). Upon entry into the ER, they presumably use the ER-associated
degradation machinery to translocate to the cytosol (Ferenczy et al., 2012). Low calcium
concentrations in the cytosol destabilizes the virions and result in an exposure of nuclear
localization signals at the N-terminus of VP1 and C-terminus of VP2 and VP3 that guide
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the transport into the cell’s nucleus. The way towards the nucleus is guided via the in-
termediate filament network and the nucleus entry is facilitated by importins (Ashok and
Atwood, 2003; Qu et al., 2004).
JC virus-like particles as delivery tool
The VLP technology is based on the recombinant expression of the VP1 protein of the
human JC polyoma virus and this biotechnological tool thereby combines the advantages
of a viral capsid and classical transfection methods to deliver foreign DNA or RNA.
Recombinant expression with self-organizing capsids has been demonstrated in, e.g. in-
sect cells or E. coli (Chang et al., 1997; Ou et al., 1999).
More importantly, the JC VLPs have similar structural features and a similar tropism
as their wild-type counterparts. Additionally, its biological characteristics regarding anti-
genicity and cellular infection are similar to the wild-type virions (Chang et al., 2011).
Immunisation studies in which rabbits had an intravenous injection of purified VP1, have
demonstrated that it did not induce an immune response, in contrast to an intramuscular
injection together with an adjuvant (Goldmann et al., 1999). There is a promising study
for the transfer to clinics in which JC VLPs were repeatedly administered in the rhesus
macaque via three di erent application routes. There were not any signs of lasting acti-
vation of the cellular or humoral immune response (unpublished data).
For DNA delivery, the viral capsid can be loaded during the recombinant expression and
co-transfection of the gene construct. Alternatively, under ambient bu er conditions, the
loading procedure can be performed with the purified protein by osmotic shock or a dis-
assembly/reassembly reaction in the presence of the DNA- or RNA-cargo. This feature
enables the packaging of only the essentially desired sequences, such as siRNAs, linear
DNA, PCR products or synthetic nucleic acids which in turn can even be delivered in
hard-to-transfect cells like the human B-cell line Raji (Goldmann et al., 1999).
JC VLP was successfully applied in a rodent model system for osteoporosis and the de-
livery of siRNAs against the osteoporosis relevant target receptor activator for nuclear
factor-kappaB ligand (RANKL). A silencing of around 30 % RANKL expression was
observed (Ho mann et al., 2016).
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1.4.1 Retargeting of virus-like particles
Retargeting of delivery tools is the attempt to render and mask the native tropism by the
attachment of exposed peptides on e.g. viral surfaces or exosomes. It is similarly possible
for VLPs.
One of the VP1 exposed loops of the murine polyomavirus were modified by the integra-
tion of an antibody-binding domain (z-protein). This allowed the binding of antibodies
and thereby to mask and alter the native tropism when used as VLPs (Gleiter and Lilie,
2001).
Utilizing this retargeting strategy for the JC VLPs, it was possible to direct the DNA
delivery to human cancer cells by switching the JC VLPs tropism towards the human epi-
dermal growth factor receptor (2 Her2/neu), that is particularly overexpressed in breast
and colon cancers (see results 3.4.2). During the course of biochemical manufacturing, it
is possible to attach nearly every targeting molecule, e.g. single chain antibodies (scFV),
to lysin residues on the VLPs surface (Figure 5). Thereby the delivery to specific cell
populations is raised, increasing its security for in vivo applications.
C-terminus
N-terminus
VP1 monomer VP1 pentamer
core-domain
outside inside
Figure 5: Structural organisation of VP1 VLPs The N-terminus of the VP1 protein sta-
bilizes the pentamer and the C-terminus connects the adjacent pentamers which
form the capsid. The outside of the core-domain exhibits lysin residues to which
retargeting molecules are attached. PDB:15VA
Additionally, infections with JCV have been reported for a wide range of cell types, such
as oligodendrocytes, astrocytes, glial cells, kidney cells, the bone marrow and B lympho-
cytes (White and Khalili, 2011; Ferenczy et al., 2012). More importantly and what still
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has to be taken into account when using the VLP as a delivery tool is that many studies
equalise the infectivity of viruses for a cell type with its ability to enter the cell. But
this can lead to confusions, as a natural virus might be able to enter the cell, not being
expressionally active because its promotor is not active in this specific cell type (White
et al., 2009). Now, using a VLP and a foreign expression cassette, the DNA is not only be
delivered in the cell, but also expressed. This was shown for JC VLPs and, e.g. HeLa cells,
in which the native virus enters but does not replicate (Suzuki et al., 2001; Qu et al., 2004).
Due to the unique features of in vitro cargo-loading and the chemical alterations of the
exposed surface to address the delivery to specific cell populations, its biological safety
can be increased and it is also a promising tool for gene therapy. VLPs do not contain any
viral nucleic acids which is an additional advantage over other delivery systems like rAAVs
and lentiviruses. Because of the non-viral gene transfer, there is no risk of recombination
with wild-type viruses in host cells and no risk of activation of oncogenes (Goldmann
et al., 1999).
1.5 Aim of the thesis
Gene transfer for research and clinics still requires more e cient gene delivery tools and
robust production pipelines. Therefore, this thesis aims to provide a platform of three
delivery tools for gene transfer to neuronal targets. Thereby we mainly addressed:
• A pipeline for rAAV production up to in vivo application.
• The straightforward generation of expression constructs with our genetic toolbox.
• An enhanced exo-AAV production by over-expression of the exosomal marker CD9.
• Production of lentiviruses for e ciency comparison.
• Safer linear DNA delivery with neurotrophic retargeted VLPs.
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2.1 Materials
2.1.1 Chemicals and enzymes
All solutions were prepared with water, purified into aqua bidest quality (ddH2O) via the
arium®pro ultrapure water system. Sterilisation of material and reagents was operated
by autoclaving or by filtration through a 0.2 µm pore size disposable filter.
The assembly of solutions is described in the corresponding context.
Table 2: Chemicals, media and enzymes
Substance Order No. Manufacturer
agar-agar KobeI 5210 Roth, Germany
AgNO3 6207.1 Roth, Germany
Acetic acid 6755.1 Roth, Germany
Ammonium persulfate (APS) 9592.3 Roth, Germany
Benzonase 250U/µl E1014-5kU Sigma, Gemany
B27 supplement 17504 Gibco, Germany
CaCl2 HNO4 Roth, Germany
C2H3NaO2 (water free) S-8750 Sigma, Germany
Coomassie Blue R250 3862.1 Roth, Germany
DMEM 31966021 Gibco, Germany
DNaseI A3778 PanReac AppliChem, Ger-
many
EGTA E3889 Sigma, Germany
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Formaldehyde 0335.2 Roth, Germany
Ethanol p.a. 5054.1 Roth, Germany
Ethidium bromide 2218.2 Roth, Germany
FCS 10500 Gibco, Germany
Glucose 6780 Roth, Germany
GlutaMAX 35050061 Gibco, Germany
Glutaraldehyde 3778.1 Roth, Germany
Glycine G8898 Sigma, Germany
HBSS 14170 Gibco, Germany
HEPES HN78 Roth, Germany
Imidazole 56750 Sigma, Germany
Iodixanol D1556 Sigma, Germany
IPTG CN08.2 Roth, Germany
Isopropanol CP41.3 Roth, Germany
KCL HN02.3 Roth, Germany
KH2PO2 P018.2 Roth, Germany
Lipofectamin 2,000 11668 Invitrogen, Germany
Lysozyme A3711 AppliChem, Germany
Methanol P717.1 Roth, Germany
MgCl2 HN03.1 Roth, Germany
MgSO4 8283.2 Roth, Germany
NaCl 3957 Roth, Germany
Na2CO3 A135.1 Roth, Germany
Na2S2O3*5H2O P034.1 Roth, Germany
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Na2HPO4 T876 Roth, Germany
Neurobasalmedia 21103 Gibco, Germany
OptiMEM 31652 Gibco, Germany
PEI P3143 Sigma, Germany
Penicillin-Streptomycin P06-07100 PAN-Biotech, Germany
Phusion High-Fidelity DNA
Polymerase
F530S Thermo Fisher, Germany
PMFS 6367.1 Roth, Germany
Rotiphorese Gel 40 (37,5:1) T802.1 Roth, Germany
SDS CN30.3 Roth, Germany
TEMED 2367.3 Roth, Germany
Taq DNA polymerase GC-002-0250 Biotherm, Germany
Tris 4088.3 Roth, Germany
Trypan Blue CN76.1 Roth, Germany
trypsin/EDTA (0.05/0.02%) P10-023100 PAN Biotech
T7 DNA polymerase EP0081 Thermo Fisher, Germany
Tween 20 9127.1 Roth, Germany
T4 DNA ligase M0202S NEB, England
Taq polymerase 3000010-02-000003 Ares Bioscence
Uranyl acetate E22400-2 Science Service, Germany
XerumFree XF205-0020-S1 TNCBio, Netherlands
Yeast extract 2363.2 Roth, Germany
39
2 Materials and Methods
2.1.2 Oligonucleotides
Desalted purified oligonucleotides were purchased from Sigma-Aldrich, Germany. They
were used in a concentration of 10 µM diluted in ddH2O.
Table 3: Oligonucleotides quantitative real-time PCR
MRB Number Description Sequence 5´-3´
298 WPRE rev CCGAAGGGACGTAGCAGAAG
305 WPRE for CTTGCCCGCTGCTGGAC
Table 4: Oligonucleotides scFv
MRB Number Description Sequence 5´-3´
501 Her2neu Xho for GGCTCGAGAAGAGAGAAGCT
503 Linker Streptavidin for GGTTCTGGTTCTATGGGCATCACCGGCACC
504 Streptavidin XbaI rev CCTCTAGAGGGCAACCAGAACCACCC
605 TrkBfor CCATGGAAGCTGAGGCTAAGTACTTG
606 TrkBCrev GGATCCTCAATGATGATGATGATGATG
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Table 5: Oligonucleotides rAAV genetic toolbox
MRB Number Description Sequence 5´-3´
230 Arch-YFP Nde for (Phos)CATATGAAGAGCAGGATCACCAGCG
231 Arch-YFP Nde rev (Phos)GGCGGCCGCCTTGCTC
253 CaMKII for GGACCTGGATGCTGACGAAG
262 eNpHR-eYFP NdeI in
for
(Phos)CATATGGGCCGCCAAGAGCAGGATC
263 eNpHR-eYFP NdeI in
rev
(Phos)GCATCATCAGCCGGGGTCC
264 hChR-
mChe/tdTo/GFP
NdeI in for
(Phos)CATATGGTGAGCAAGGGCGAGGAG
265 hChR-mChe NdeI in
rev
(Phos)CATGGTGGCGGCCGCTGG
266 ArchT-GFP NdeI in rev (Phos)TGCTACTACCGGTCGGGGC
298 WPRE rev CCGAAGGGACGTAGCAGAAG
Table 6: Oligonucleotides MIDGE
MRB Number Description Sequence 5´-3´
213 rev CAG-GFP TCTCCCCCTGAACCTGA AAC
214 for pAAV-CAG GATCGTACCATTGACGTCAATAATG
308 WPRE out for (Phos)TCGATACCGTCGACCCG
309 WPRE out rev (Phos)TTATCGATAAGCTTGATATCGAATTC
462 MIDGE 1 (Phos)CGCGTCTTTTGACGCGCATG
463 MIDGE 2 (Phos)CGCGTCTTTTGACGCGAGCT
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2.1.3 Machines
Table 7: Machines with model and manufacturer
Machine Model Manufacturer
Balance EG 620-3NM & Kern Sohn GmbH, Germany
Bioruptor Bioruptor® Pico Diagenode, Belgium
Chemiluminescence system ChemoCam Imager INTAS, Germany
Centrifuge Heraeus Megafuge 8R Thermo Fisher Scientific, USA
Centrifuge Heraeus Fresco21 Thermo Fisher Scientific, USA
Ultracentrifuge Avanti J-30I Beckman Coulter, USA
Fluorometer Qubit 2.0 Life Technologies, USA
Freezer (-20°C) Bosch, Germany
Freezer (-80°C) MDF-DU500VH-PE Panasonic, Japan
Freezer (-150°C) ULT7150-9-D Thermo Fisher Scientific, USA
Flow cytometer LSR II Flow Cytometer BD Bioscience, USA
Gel documentation system Gel iX Imager INTAS, Germany
Ice machine ZBE 70-35 Ziegra, Germany
Cell culture incubator Heracell VIOS 160i Thermo Fisher Scientific, USA
Plate incubator IN75 Memmert, Germany
Microscope Axio Vert. A1 Zeiss, Germany
PCR thermocycler Labcycler Sensoquest, Germany
pH meter SevenCompactTM S210 Mettler Toledo, USA
Plate reader Synergy 2 BioTek, USA
Platform rocker PMR-30 Grant bio, UK
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Power supply Beckman Consort bvba, Belgium
Real-Time PCR System 7500 Real-Time PCR System Applied Biosystems, USA
Real-Time PCR System StepOneTMPlus Real-Time
PCR System
Applied Biosystems, USA
Rotor JS-24.38 Beckman Coulter, USA
Rotor JA-30.50 Beckman Coulter, USA
Safety cabinet Safe 2020 Thermo Fisher Scientific, USA
Shaking incubator Ecotron Infors HT, Switzerland
Sonifier Sonifier 250 BRANSON, USA
Stereo microscope SZ51 Olympus, Germany
Thermoblock ThermoStat plus Eppendorf, Germany
Tissue slicer 51425 Stoelting, Ireland
Ultrapure water system arium®pro Sartorius, Germany
Vortexer Vortex-GenieTM 2 Scientific Industries, USA
Water bath WNB10 Memmert, Germany
Western blot chamber XCell SureLock® MiniCell Life Technologies, USA
2.2 Molecular biology
2.2.1 Enzymatic digestion of DNA
For an enzymatic digestion of DNA in order to create new constructs or confirm the com-
position of a plasmid the manufacturer´s protocol was followed. Digestion samples were
incubated between 30 min and 4 h at 37°C. The gained DNA fragments were separated
by agarose gel electrophoresis (2.2.7) and further purified as described in 2.2.8.
2.2.2 Ligation of DNA
For the creation of a new plasmid around 300 ng insert DNA and around 10 ng of the
larger plasmid backbone DNA were mixed with 5 µl reaction bu er and 1 µl of T4 DNA
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ligase. It was filled up to a total volume of 50 µl and incubated over night at 4°C or for
half an hour at RT.
The ligation mixture was immediately used for transformation or stored at -20°C until
use.
2.2.3 Transformation of E.coli
Competent E.coli strains for plasmid transformations were prepared with the Mix &
Go E.coli Transformation Kit (Zymo Research, USA) according to the manufacturer´s
instructions. Aliquots of the competent cells were stored at -20°C and thawed on ice before
use. A few µl of a ligation mixture or plasmid preparation were incubated with the cells
for 2 min on ice. Using plasmids coding for an Amp resistance the transformation mixture
was immediately spread on an LB-plate containing Amp. In the case of other resistances,
the transformation mixture was previously incubated for 1 h at 37°C, at 300 rpm in four
volumes of SOC medium. Colonies grew over night at 37°C.
Table 8: LB medium
LB medium
NaCl 10 g
tryptone 10 g
yeast extract 5 g
Fill up to 1 L with ddH2O and sterile autoclave. 15 g of agar-agar KobeI was added for
agar plates before autoclaving.
Table 9: SOC medium
SOC medium 1 L
NaCl 10 mM
tryptone 20 g
MgCl2 10 mM
MgSO4 10 mM
Add 20 mM glucose after autoclaving.
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Table 10: Antibiotic concentrations in LB media
Antibiotic Concentration
Ampicillin 100 µg/ml
Kanamycin 50 µg/ml
ZeocinTM 100 µg/ml
Table 11: E.coli strains
Strain Genotype Source
One Shot®Stbl3TM Chemi-
cally competent cells
F-mcrB mrrhsdS20(rB-, mB-)
recA13 supE44 ara-14 galK2
lacY1 proA2 rpsL20 (StrR)
xyl-5 ⁄-leumtl-1
Thermo Fisher Scientific, USA
One Shot®TOP10 Chemically
ompetent E.coli
F- mcrA   (mrr-hsdRMS-
mcrBC) 80lacZ M15  
lacX74 recA1 araD139
 (araleu)7697 galU galK
rpsL (StrR) endA1 nupG
Thermo Fisher Scientific, USA
SoluBL21® F- ompT hsdSB (rB- mB- ) gal
dcm (DE3)†
Invitrogen, Germany
BL21 Star®(DE3) F- ompT hsdSB (rB-mB-) gal
dcm rne131 (DE3)
Invitrogen, Germany
2.2.4 Purification of E.coli plasmids
Large scale preparation of E.coli plasmids was performed with the ZymoPURE™ Plasmid
Midiprep Kit (Zymo Research, Germany) and 50-100 ml over night bacterial culture per
column, according to the manufacturer´s protocol.
For a small scale plasmid purification a 5 ml over night culture of the bacterial strain was
inoculated. 1.9 ml culture was centrifuged at 21,000X g for 2 min.
The pellet was resuspended in 150 µl P1, and the same volume of P2 was added. The
tubes were inverted several times and incubated for 5 min at RT before 150 µl P3 was
45
2 Materials and Methods
added and the tubes were inverted again. The cell debris was pelleted and the supernatant
mixed with 500 µl isopropanol.
A centrifugation with 21,000X g for 20 min at 4°C pelleted the DNA, which was washed
with 500 µl 75 % ethanol subsequently. The dried DNA pellet was resuspended in 100 µl
ddH2O.
P1
tris pH 8 50 mM
EDTA pH 8 10 mM
RNase A 10 µg
P2a
NaOH 400 mM
P2b
SDS 2 %
Mix P2a and P2b before use.
P3
KAc 3 M
Fill up with ddH2O and adjust pH to 4.8 with acetic acid.
2.2.5 Polymerase chain reaction
Polymerase chain reaction (PCR) is a method to amplify DNA sequences in vitro in a
three step reaction. First, the dsDNA is denaturated at 95°C, second at a lower temper-
ature the primers anneal to the single strand DNA template, after that third the DNA
polymerase elongates the primers to the complementary strand. With multiple repeats of
that cycle, the region between the two primers is exponentially amplified.
46
2 Materials and Methods
Here, the Taq polymerase and Phusion polymerase were used according to the manufac-
turer´s protocol with primers listed in table 3.
A 5´ phosphorylated primer pair, of which one primer had an overhang of the restriction
side nucleotide sequence, was used to insert restriction sites in plasmids. The purified PCR
product was recircularized with a standard ligation procedure and hereupon transformed
in E.coli for further amplification.
2.2.6 Quantitative real-time PCR
Quantitative real-time PCR was used according to Rohr et al. (2002) to determine the
concentration of AAV vector genomes (the genomic titer). Therefore the SensiMixTM
SYBR® Low-ROX Kit and SensiMixTM SYBR® Hi-ROX Kit (Bioline, UK) was used
to set up a master mix with primers #298 (5´-CCGAAGGGACGTAGCAGAAG-3´) and
#305 (5´-CTTGCCCGCTGCTGGAC-3´) according to the manufacturer´s protocol. 1 µl
sample was added to 19 µl master mix per 96-well plate well. The PCR run itself was
performed with 7500 Real-Time PCR System or StepOneTM Plus Real-Time PCR System
and evaluated with 7500 System SDS Software, respectively StepOneTM Software.
A ten-time dilution series ranging from 103 templates/µl to 108 templates/µl dsDNA was
measured on the same plate to create a standard row according to which the concentration
of viral vector genomes was calculated. Taking into account that the AAV genome is a
ssDNA and to gain vector genomes per ml the value was doubled and multiplied by a
factor of 1,000.
The 4,464 bp long template DNA fragment was obtained by an enzymatic restriction
digest of the plasmid pAAV-CaMKII-eNpHR3.0-eYFP with the enzyme SdaI, followed by
a separation of the backbone by agarose gel electrophoresis and purification as described in
2.2.8. Its concentration was measured by Qubit 2.0 and aliquots of the standard dilution
row were stored at -80°C.
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Table 12: Real-time PCR program
Duration Temperature (°C) Step
10 min 95 holding stage
15 sec 95 40X cycling stage
1 min 60
15 sec 95 melting curve
1 min 60
+0.3
15 sec 95
2.2.7 Agarose gel electrophoresis
Two-dimensional agarose gel electrophoresis is a method to separate DNA fragments ac-
cording to their size. The gel consisted of 1X TAE bu er with 1 % or 2 % agarose. The
samples were prepared with 6X loading dye (Thermo Fisher Scientific, Germany) and sep-
arated on an agarose gel using a field strength of 120 V. A DNA marker (GeneRuler 1 kb
DNA Ladder, Thermo Fisher Scientific, Germany) was used to determine the fragment
size. Visualization of nucleotide fragments was performed after staining in an ethidium
bromide bath (1:1000 in ddH2O) with a gel documentation system.
Table 13: 50X TAE bu er
Substance Concentration
Tris base 2 M
EDTA 50 mM
acetic acid 1 M
Fill up with ddH2O and adjust pH to 8.0.
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2.2.8 DNA isolation from agarose gels and PCRs
DNA in agarose gels was purified with QIAquick Gel Extraction Kit and DNA from PCR
reactions was purified with QIAquick PCR Purification Kit (Qiagen, Germany) according
to the manufacturer´s protocol.
2.2.9 MIDGE vector production
MIDGE vector production was performed according to Schakowski et al. (2001). The
CAG-GFP expression construct was amplified from the pAAV-CAG-GFP plasmid (Ad-
dgene #28014) (for #214, rev #213). The amplicon was transferred via TA-cloning
into the pGEM®-T Easy vector (Promega, Germany) to generate pGEM-T easy-CAG-
GFP-WPRE. Woodchuck hepatitis virus posttranslational regulatory element (WPRE)
sequence was removed by PCR-amplification of the plasmid, followed by self-ligation (for
#308, rev #309). For the MIDGE vector generation, the pGEM-CAG-GFP-WPRE was
linearized with SacI and SphI followed by purification of the 1.9 kb DNA fragment as
described in 2.2.8.
2 µg DNA was ligated over night at 16°C with 8 µl T4 Ligase and each 6.4 µl of 100 µM
#462 and #463. DNA was purified using QIAquick PCR Purification Kit (Qiagen, Ger-
many) before unligated oligonucleotides as well as not re-linearised DNA was digested
with T7 DNA Polymerase. Therefore 1.5 µg DNA was incubated with 60 U T7 DNA
Polymerase in a volume of 300 µl for 6 h at 37°C and the reaction was stopped with an
incubation of 20 min at 75°C. The MIDGE vectors were purified using the QIAquick PCR
Purification Kit.
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2.3 Cell biology
2.3.1 Cell culture
Cells were splitted twice a week and cultivated at 37°C with 5 % CO2 in a humidified
atmosphere in T-75 or T-175 cell culture flasks (Sarstedt, Germany). The media was
supplemented with penicillin/streptomycin (100 Units/ml, 0.1 mg/ml) and additional
supplements listed in table 14.
Table 14: Cell lines and cultivation
Cell line Tissue Source Media FCS (%)
HEK-293 embryonic kidney,
human
ATCC® CRL-1573TM DMEM 10
HeLa cervix carcinoma,
human
ATCC® CCL-2TM RPMI 10
SH-SY5Y neuroblastoma, human ATCC® CRL-2266TM DMEM/F-12 10
SKBR3 breast carcinoma,
human
ATCC® HTB-30TM DMEM 10
AAV-293 HEK-293 transformed
with human adenovirus
type 5 DNA
Agilent Technologies,
USA
DMEM * 15
3T3 fibroblasts, murine a gift from Felix B. En-
gel, University Medical
Center Erlangen
DMEM 10
* supplemented with 1 mM sodium pyruvate and 1 mM L-glutamine.
2.3.2 Primary material
Cortex tissue was gained from animal euthanisations for approved experiments, where
the cortex was not used for the project. Rodent material was given from Camin Dean´s
group (European Neuroscience Institute, Göttingen) and NHP material from the German
Primate Center (Göttingen).
Mesenchymal stem cells, isolated from the Wharton´s jelly of the human umbilical cord,
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were gained from a BMBF project cooperation with the Hemocentro Distrital (Bogota,
Colombia). The anonymized donors approved the use of the MSCs for research.
Table 15: MSC donors
Anonymised donor
number
Sex
#83 female
#97 female
#108 male
2.3.3 Primary cortical cultures
Primary cortical cultures were prepared according to Shimada et al. (1969) and Fischbach
(1972) with minor modifications. For a co-cultivation of neurons and glia cells cortices
of E18 Wistar rats and Callithrix jacchus, Macaca fascicularis and Macaca mulatta of
di erent ages were used.
Dissociated cultures The cortices were freed from meninges and cut into small pieces in
ice-cold dissection media followed by 30 min incubation in trypsin/EDTA (0.05/0.02%).
Afterward, the tissue was washed with dissection media and the cells were singularized
by trituration in first-day media. The cell suspension was filtered through a 100 µm cell
strainer (Greiner Bio-One, Germany) and the cell number counted with Trypan Blue.
40,000 to 80,000 cells in 500 µl first-day media were seeded in 24-well plates with PEI-
treated (0.05 % for 5 h) glass cover slips. Cells were cultured at 37°C with 5 % CO2 in
a humidified atmosphere. After one day media was changed to neurobasal media and at
day seven Ara-C was added to a final concentration of 5 µM to prevent mitotic growth of
glia cells.
Organotypical brain slices The cortices were freed from meninges in ice-cold dissection
media and pieces of the favored area were prepared by using forceps and scalpel. What-
man paper (sterilized in 70 % EtOH and dried) was placed on the desk of the tissue slicer,
pre-wet with dissection media. The tissue was placed on it and sliced into 300-400 µm
thick slices. Up to six slices were cultivated on a membrane inlet (CatNo. PICMORG 50,
Merck Millipore, USA), placed on 1.1 ml of dissection media with glucose. Media was
changed every 2-3 days.
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Table 16: Dissection media
Substance Concentration
Glucose 33 mM
HEPES 10 mM
HBSS
Table 17: First-day media
Substance Concentration
FCS 10 % (v/v)
GlutaMAX 2 mM
P/S 1X
DMEM
Table 18: Neurobasel media
Substance Concentration
B27 supplement 2 % (v/v)
GlutaMAX 2 mM
P/S 1X
Neurobasal media
2.3.4 Lipotransfection of cells
For lipotransfection of cells grown in a 24-well plate, the transfection conditions were as
follows: per well 50 µl of pre-warmed OptiMEM were blended with 1 µl Lipofectamin
2,000, another 50 µl was blended with 0.1 to 1 µg of DNA. After an incubation of 5 min,
both mixtures were combined and incubated for another 20 min.
The transfection mixture was added dropwise to the cells, and the plate was gently shaken
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to distribute the transfection agent. Depending on the DNA construct the expression
could be expected after one day of cultivation.
2.3.5 rAAV production
For a small scale production a 15 cm tissue culture dish cell+ (CatNo. 83.1803, Sarst-
edt, Germany) was used and for large scale production a Thermo ScientificTM NuncTM
EasyFillTM Cell FactoryTM Systems (Thermo Fisher Scientific, USA) was used. This pro-
tocol gives the values for the production in 15 cm tissue culture dishes and the values for
the production calculated for one layer of a NuncTM EasyFillTM Cell FactoryTM System
in brackets.
At the first day of the production, 5x106 (1,8x107) AAV-293 cells of maximal passage
10 were seeded in 30 ml DMEM (107 ml) and cultivated for two days.
At the third day, 73,6 µg (263.48 µg) helper&packaging plasmid (Plasmid Factory, Ger-
many) and 18,4 µg (65.87 µg) rAAV plasmid were mixed in a 50 ml conical tube with
1.109 ml (4 ml) 500 mM CaCl2.
Under constant shaking 1.109 ml (4 ml) 2X HBS were added and mixed by producing
air bubbles with the pipette. The transfection mixture was incubated for 5 min. Next,
media from the cell culture was changed to 12 ml (43 ml) DMEM-F12 (supplemented with
2 % FCS and penicillin/streptomycin (100 Units/ml, 0.1 mg/ml)) and the transfection
mixture was added dropwise. For the Cell Factory System, the transfection mixture was
added to the DMEM-F12 before it was filled in.
After 8 h incubation, the media was changed to 30 ml DMEM (107 ml), and the cells
were cultivated for another 40 h.
At day five the rAAV comprehending cells were harvested. Therefore cultivation me-
dia was removed carefully, 0.5 ml 1X gradient bu er was added and the cells removed
with a cell scraper (Sarstedt, Germany) and collected in tubes.
For the cell factory cells were detached with 25 ml trypsin, the cells collected, washed
with media and resuspended in 1X gradient bu er.
Cells were lysed by freezing in liquid nitrogen or at -150°C and thawed in a 55°C water
bath. For mechanical disruption, the lysate was transferred through a 26 gauge needle
(CatNo. L10101, NEOPOINT, Germany) followed by three cycles of freeze-thaw. The
lysate was cooled to 37°C and 500U Benzonase per 1 ml lysate was added, incubated for
1 h at 37°C and mixed every 15 min.
Cell debris was pelleted by centrifugation at 3,000X g for 15 min at 4°C. The virus con-
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taining crude cell lysate was stored at 4°C until use or further purification.
Table 19: 20X HBS
Substance Concentration (M)
NaCl 2.8 M
Na2HPO4 15 mM
HEPES 0.5 M
Adjust to pH 7.1 and sterile filter with 0.2 µm filter.
2.3.6 exo-AAV production
The production and harvesting protocol of exo-AAVs was adapted from György et al.
(2014). Recombinant HEK-AAV-CD9GFP cells were gained by transduction of HEK293
cells with the lentivirus LV-CD9GFP-VSV-G (Kindly provided by Dr. Kai Böker, German
Primate Center, Göttingen) and used for rAAV production when at least 80 % of cells
were determined by flow cytometry analysis to express GFP. Exo-AAVs were produced in
HEK-AAV cells, seeded in four 15 cm dishes 48h prior to transfection. Calcium phosphate
transfection was performed in DMEM-F12 with penicillin/streptomycin and 2 % FCS.
Per plate 73.6 µg helper&packaging plasmid and 18.4 µg pAAV-CAG-GFP were applied.
After 8h the media was changed to DMEM, supplemented with penicillin/streptomycin,
2 % FCS, 1 mM sodium pyruvate and 1 mM L-glutamine. The next day, media was
changed to 10 ml DMEM, supplemented with penicillin/streptomycin, 1 mM sodium
pyruvate, 1 mM L-glutamine and 2 % exosome-free FCS (16h at 100k X g depleted FCS)
and cells were cultivated for two days.
Exo-AAVs were harvested from the media of four plates, which was depleted at 300X g for
5 min and at 1000X g for 10 min. The supernatant was centrifuged at 20kX g for 1 h at
15°C. The pellet was resuspended in 200 µl DMEM and the supernatant was centrifuged
again at 100kX g for 1.5 h at 15°C and the pellet as well resuspended (exo-AAV). The
samples were kept at 4°C until use.
2.3.7 Reference rAAVs from the Viral Vector Core
In this thesis, later referred as purchased reference virus, we applied following viruses from
the Viral Vector Core, University of North Carolina (UNC), Chapel Hill, North Carolina,
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USA.
Table 20: Standard rAAVs from the Viral Vector Core
rAAV2/5-CaMKII-Jaws-KGC-GFP-ER2
rAAV2/5-CaMKII-eNpHR3.0-mCherry-WPRE
rAAV2/5-CaMKII-hChR2(H134R)-eYFP-WPRE
rAAV2/5-SSpEMBOL-CBA-GFP
rAAV2/5-CaMKII-eArchT3.0-eYFP
rAAV2/5-CaMKIIa-hChR2(H134R)-eYFP-WPRE
2.3.8 Iodixanol density gradient
To eliminate cell debris and empty rAAVs the crude cell lysate was loaded on an iodixanol
gradient consisting of four di erent layers (Adapted from Zolotukhin et al. (1999)). The
gradient was centrifuged at 104,000X g for 15 h at 4°C in a JS 24.38 rotor for Avanti J-30I
(Beckman Coulter). The twelve bottom low fractions were collected in 1 ml aliquots with
the rAAVs accumulated in the 40 % phase. Aliquots were stored at -80°C.
Table 21: Iodixanolgradient
Volume (ml) OptiPrep60 (%)
9.7 15
6.4 25
5.4 40
5.4 58
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Table 22: Iodixanol gradient solutions in ml
15 % 25 % 40 % 58 %
Total 20.5 ml 14 ml 12 ml 12 ml
Iodixanol 5.125 5.74 8 11.6
10X GB 2.05 1.375 1.2 0.4
5 M NaCl 4.1 - - -
ddH2O 9.225 6.885 2.8 -
Table 23: 10X Gradient bu er
Substance Concentration (M)
Tris pH 7.6 1
NaCl 5
MgCl2 1
Fill up with ddH2O and sterile filter with 0.2 µm filter.
2.3.9 Analytical iodixanol gradient
To separate vesicles, standard rAAVs and exo-AAVs dependent on its density an analytical
discontinuous iodixanol gradient with 14 fractions of increasing iodixanol concentrations
from 6-60 % in PBS was performed (With modifications from Dettenhofer and Yu (1999)).
The virus samples were applied in DMEM and the gradient centrifuged for 16 h at 4°C
and 103,000 x g. The gradient was harvested in 18 fractions of 1 ml from top to bottom.
2.3.10 Dialysis and concentration of rAAVs
rAAVs in iodixanol were dialysed over night in 5 L PBS-MK at 4°C. Therefore the dialyse
membrane Spectra/Por® with a MWCO of 100,000 Da (Roth, Gemany) was used.
All centrifugation steps were carried out at 3,200X g for 10 min. The dialysed rAAV
sample was centrifuged to test whether a precipitate was formed during dialysis. After
this centrifugation, the sample was filled up to 20 ml with PBS-MK, and centrifuged
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again. A Vivaspin 20 concentrator (Rettberg, Germany) with an MWCO of 100,000 Da
was washed with 20 ml PBS-MK and the pre-diluted rAAV sample was loaded on the
concentrator and centrifuged until less than 1 ml volume remained. The rAAV was washed
three times with 20 ml PBS-MK, and the last centrifugation step was prolonged until the
volume decreased to less than 250 µl.
Table 24: PBS-MK
Substance Concentration
NaCl 13.7 mM
Na2HPO4 1.01 mM
KH2PO4 1.76 mM
MgCl2*6H2O 0.05 mM
KCl 0.395 mM
2.3.11 Lentivirus production
Lentiviral constructs were generated via enzymatic digestion and subsequent ligation as
followed:
pLenti-hSyn-GFP was generated from pAAV-CAG-GFP (see table 43) and pLenti-hSyn-
eNpHR3.0-eYFP (a gift from Karl Deisseroth, Addgene #26775) with EcoRI and XbaI
restriction sites.
pLenti-CAG-GFP was generated from pAAV-CAG-GFP (a gift from Karel Svoboda, Ad-
dgene #28014) and pLenti-hSyn-eNpHR3.0-eYFP (a gift from Karl Deisseroth, Addgene
#26775) with EcoRI and PacI restriction sites.
pLenti-CaMKII-GFP was generated from pAAV-CaMKII-GFP (see table 43) and pLenti-
CaMKII-eNpHR3.0-eYFP (a gift from Karl Deisseroth, Addgene #26971) with EcoRI
and BamHI restriction sites.
All plasmids were checked for functionality via lipotransfection in HEK or HeLa cell lines
and microscopic detection of reporter gene expression (data not shown).
For lentivirus production 1x106 HEK293FT cells were seeded in 3 ml media per well in a
6-well plate. Right afterward the cells were transfected via calcium phosphate transfection
with three plasmids: psPAX2 (a gift from Didier Trono, Addgene #12260), pLP-VSV-G
(a gift from Bob Weinberg , Addgene #8454) and pLenti-hSyn-GFP, pLenti-CAG-GFP
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or pLenti-CaMKII-GFP. The next day, media was exchanged and centrifuged at 700X g
and the virus containing supernatant stored at 4°C. The cell pellet was returned in the
well, and sodium butyrate added. After 8 h and on the next day, the media was again
exchanged and the supernatant collected. One day later the media was harvested, pooled
with the previous collected media and filtered through 0.45 µm pore size. The virus
sample was stored at 4°C.
2.3.12 Flow cytometry analysis
Cells were trypsinised, centrifuged at 300X g for 5 min and washed three times with PBS.
The cells were fixed with 2 % PFA in PBS for 30 min at 4°C followed by three washing
steps. For the measurement, the cells were resuspended in a few hundred µl of PBS. Cells
were analysed with the BD LSR II system (BD, USA) the 505LP - BP530/30 filter set
for GFP detection and the FACSdiva software. The data were analysed with the Flowing
Software and plotted with either GraphPad Prism 6 or R.
Table 25: 4 % Paraformaldehyde
Substance Concentration
PFA 4 % (w/v)
10X PBS 10 % (v/v)
ddH2O 130 ml
1 M NaOH -
Heat up to 60 °C under constant stirring. If it does not solve add more NaOH. Cool down
and adjust the pH to 7.2-7.4. Fill up to 200 ml and filter through 0.2 µm, store at -20°C.
Table 26: 10X PBS
Substance Concentration (M)
NaCl 1.37
KCL 0.027
Na2HPO4 0.091
KH2PO4 0.02
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2.3.13 Determination of transducing units by flow cytometry
The concentration of transducing units of rAAV samples, the functional titer, was deter-
mined by flow cytometry analysis adapted from Kutner et al. (2009).
6X 104 HeLa cells per 12-well plate well were seeded in RPMI media. The virus was
diluted in six steps in a 3:5 serial dilution in OptiMEM with 2 % XerumFree. 6 h after
seeding, the media from the cell culture was replaced with 1 ml of the diluted virus. Cells
were harvested 48 h after transduction, prepared and analysed by flow cytometry anal-
ysis as described in 2.3.12. The percentage of GFP positive cells was used to calculate
the total amount of transduced cells, assuming 6X 104 HeLa cells. The amount of GFP
expressing cells was plotted against the volume of applied virus per well, and a linear
regression was applied. The TU/ml are given by the y-value for 1 ml.
2.3.14 PEG precipitation of vesicles
The protocol for PEG precipitation was adapted from Alvarez et al. (2012) and Antes
et al. (2015). In brief, the vesicle containing media was depleted at 500 x g for 5 min
and at 2,000 x g for 30 min. The supernatant was filtered through 0.45 µm filter device
and mixed with 16.6 % PEG (1:5 PEG8000 in PBS). The mixture was incubated under
constant rotation at 4°C for 16 h and vesicles isolated by centrifugation at 1,500X g for
30 min. The pellet was resuspended in PBS or DMEM.
2.3.15 Nanoparticle tracking analysis
Extracellular vesicles were analysed with the NanoSight LM10 instrument (Malvern In-
struments Ltd, UK) with a recording time of 30 sec. The data were processed with the
NTA software 2.3 (Dragovic et al. (2011)).
2.3.16 VLP packaging and transduction
VLPs consisting of the modified VP1 protein from the human JC polyoma virus were pro-
duced in Hi5 cells and provided as around 2 µg/µl concentrated aliquots in reassociation
bu er by Dr. Stefan Schneider (German Primate Center, Göttingen).
Befor cargo loading, the VLPs were incubated in 1X dissociation bu er with 10 mM
DTT for 30 min to disassemble into pentamers. Around 500 ng DNA was added and
after another 30 min incubation the sample was dialysed over night in 10,000 MWCO
Slide-A-Lizer (Thermo Scientific, Germany) in 5 l reassociation bu er at 4°C. Cells were
transduced in OptiMEM with 2 % XerumFree or the corresponding media without sup-
plements, and it was changed to the supplemented media after over night incubation.
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Table 27: Reassociation bu er
Substance Concentration
HEPES 10 mM
NaCl 150 mM
CaCl2 1 mM
Adjust to pH 7.5 with 5 M NaOH.
Table 28: 10X Dissociation bu er
Substance Concentration
HEPES pH 7.5 100 mM
EGTA 150 mM
NaCl 1.5 M
2.3.17 VLP retargeting
For retargeting of the VLPs, loaded with the linear CAG-GFP expression cassette, the
crosslinker SM(PEG)6 (Thermo Scientific, USA) was added to a 100x molar excess and
the sample incubated for 1 h at RT. Thereby a VLP contains 360 binding sites and 1 µg
equates to 7.52x 10-5 nmol. The unbound crosslinker was removed by 1h dialysis against
reassembly bu er in a Slide-A-Lyzer.
The peptide RVGN6 was incubated for 1 h at RT with 15 mM DTT to reduce its n-
terminal cystein for crosslinking and subsequently the excess DTT was removed by 1h
dialysis in 100-500 MWCO membrane against reassembly bu er.
VLPs with crosslinker were combined with the reduced peptide in 10x molar excess and
dialysed for 1h in a Slide-A-Lyzer before used for transduction.
The modified retargeting protein RVGN6 based on the sequence published from Javed
et al. (2016) was ordered from GeneCust (GeneCust, Luxembourg): H-Thr-Pro-Cys-Asp-
Ile-Phe-Thr-Asn-Ser-Arg-Gly-Lys-Arg-Ala-Ser-Asn-Gly-Ser-Gly-Ser-Cys-OH.
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2.3.18 Microscopy
Phase and fluorescence microscopy pictures were taken at the Axio Vert.A1 (Zeiss, Ger-
many) with the filter set P 525/50 (GFP/YFP) and the filter set BP 605/70 (RFP/mCherry/tdTomato).
Electron microscopy was performed using 200 mesh formvar and carbon coated copper
grids (Electron Microscopy Science, USA) and observation was performed with the elec-
tron microscope EM10A/B (Zeiss, Germany). The rAAV sample, pure or diluted 1:10
in Sorensen´s bu er solution with PFA, was deposited on the UV-exposed grid for 5-40
min, followed by 5 wash steps with ddH2O and 3 s incubation in 2 % uranyl acetate. To
inactivate the rAAVs the grid was exposed for 20 min to UV-light.
Table 29: Sorensen´s bu er solution with PFA
Substance Concentration
Na2HPO4 26.75 mM
KH2PO4 6.5 mM
PFA 4 %
2.3.19 Voltage clamp recording
The voltage clamp measurement was performed together with Dr. Markus Stahlberg at
the European Neuroscience Institute, Göttingen. HeLa cells were cultivated on a glass
cover slip and transduced with rAAV2/5-CAG-GFP. The experiment was performed with
an inverted Zeiss Axio Observer.Z1 equipped with a 100 mW OPSL laser module for
stimulation at 488 nm. The photocurrent response was recorded after a 500 µs pulse with
5 % laser intensity at 488 nm. For detailed information see Stahlberg (2016).
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2.4 Protein biochemistry
2.4.1 Protein expression in E.coli
Generation of pET28a(+) expression vectors: pPICZ–A-TrkBscFv was kindly provided
by Dr. Stefan Lüdtke and pPICZ–A-Her2neu-Streptavidin was kindly provided by Dr.
Stefan Schneider. Pichia pastoris (P. pastoris) expression construct pPICZ–A-TrkBscFv-
Streptavidin was gained by overlap extension PCR with pPICZ–A-Her2neu-Streptavidin
and primers #503 and #504, and pPICZ–A-TrkBscFv with primers #501 and #504.
Both PCR-products were used as template in a PCR with primers #501 and #504. The
purified PCR product was blunt-end ligated in pJet1.2/blunt (Thermo Scientific, Ger-
many). Subsequently, pJet1.2-TrkBscFv-Streptavidin and pPICZ–A were digested with
XhoI and XbaI and pPICZ–A-TrkBscFv-Streptavidin generated by ligation of the frag-
ments.
pET-28a-TrkBscFv-Streptavidin was generated by enzymatic digestion of pJet1.2-TrkBscFv-
Streptavidin and pET28a(+) with NcoI and BamHI und subsequent ligation of the frag-
ments.
pET-28a-TrkBscFv was generated by PCR amplification of pPICZ–A-TrkBscFv with
primers #605 and #606 and subsequent blunt end ligation in pJet1.2/blunt. pJet1.2-
TrkBscFv and pET28a(+) were digested with NcoI and BamHI and the fragments ligated.
The corresponding plasmid maps are attached in the appendix.
Recombinant proteins were expressed in E.coli SoluBL21® or BL21 Star with the pET-
28a(+) vector system. The recombinant strain was used to inoculate a 3 ml over-night
culture and used at the next day to start a 50 ml culture over night. At the day of
expression, 100 ml were inoculated with the over-night culture to an OD600 of 0.4 and
grown at 37°C until OD600 reached around 0.6. The protein expression was induced with
0.5 mM IPTG and the culture was harvested after several hours.
2.4.2 Protein extraction
Proteins expressed in E.coli were purified in small scale for an analytical expression and
large scale for FPLC purification.
Whole cell protein isolation 1 ml aliquots of the culture were centrifuged at 5,000X g for
10 min. The pellet was resuspended in 50 µl 2X Laemmli bu er and incubated at 95°C
for 5 min. 50 µl ddH2O were added and the sample heated again. The OD600 at each
sampling time point was measured, and according to this, all samples were diluted with
1X Laemmli to an OD600 of 0.5. Before loading 5 µl on a SDS-PAGE, the sample was
heated up again and centrifuged for 1 min at 21,000X g.
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Soluble cell protein isolation 4 ml aliquots of the culture were centrifuged at 3.000X g
for 10 minutes. The pellet was resuspended in lysis bu er (PBS with PMSF, lysozyme,
MgCl2, and DNaseI) and incubated for 1 h on ice on a shaker. 300 µl of the sample were
lysed with the Bioruptor in 15 cycles of 60 sec sonification and 60 sec cooling break. The
sample was centrifuged for 10 minutes at 21,000X g at 4°C and the supernatant mixed
with 6X Laemmli. 10 µl were loaded on a SDS-PAGE.
Large scale extraction of soluble proteins was performed for FPLC purification. Therefore,
1 g of bacteria pellet was resuspended in 6 ml lysis bu er and incubated for 1 h on ice on
a shaker. The cells were disrupted by repeated passages through a microfluidizer.
The cell debris was removed by centrifuged at 54,000X g for 20 min at 4°C and the
supernatant used for FPLC purification.
2.4.3 Protein purification (FPLC)
Recombinant proteins with a 6XHis-taq were purified with ÄKTA avant (GE Healthcare,
UK) and a 1 ml HisTrap TM excel column. The system was run with PBS and the protein
was eluted with an imidazole gradient up to 300 mM (pH 7.2).
rAAV purification was performed with the columns and bu ers cited in table 40. The elu-
tion step was performed as a gradient and the fractions collected in 1 ml. The abundance
of virus was tested via real-time PCR, transduction of cell lines or dot blot.
2.4.4 TCA protein precipitation
The protein sample was incubated with 10X RIPA bu er (150 mM sodium chloride, 1
% Triton X-100, 0.5 % sodium deoxycholate, 0.1 % SDS and 50 mM Tris, pH 8.0) for
10 min on ice. 1 volume of 50 % TCA was added to four volumes of the protein sample
and incubated for another 10 min. The tube was spun at 13000 rpm for 5 min at 4°C
and the pellet was washed three times with cold acetone. The dried pellet was dissolved
in Laemmli bu er.
2.4.5 SDS-PAGE, Coomassie and Western blot
SDS-PAGE 1.0 mm cassettes (NC2010, Novex, Germany) were poured and run in XCell
SureLock™ Mini-Cell Electrophorese Cell (Life Technologies, UK). 3 µl of the PageRuler
Prestained Protein Ladder (Thermo Fisher, Germany) were used for determination of
protein weight and the protein samples were prepared with 6X Laemmli bu er. The
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system was run with 1X electrophorese bu er for 30 min at 45 V and maximal A, afterward
at 80 V until the desired protein separation.
Table 30: 5X Electrophorese bu er
Substance Concentration
Tris 125 mM
Glycine 1.25 M
SDS 10% (w/v)
Table 31: 10% SDS-PAGE
Substance Amount
Separating gel (10%)
H2O 3.563 ml
40% acrylamid 1.875 ml
1.5 M Tris pH 8.8 1.875 ml
10% SDS 75 µl
10% APS 75 µl
TEMED 7.5 µl
Stacking gel (6%)
H2O 2.745 ml
40% acrylamid 0.47 ml
1 M Tris pH 6.8 0.47 ml
10% SDS 37.6 µl
10% APS 37.6 µl
TEMED 3.76 µl
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Coomassie stain Proteins in the gel were stained with coomassie stain solution and ex-
cessive dye was removed in destainer solution until only the protein lanes were visible.
Table 32: Coomassie stain
Substance Concentration
Coomassie Blue R250 0.2%
Acetic acid 7.5%
EtOH 50%
Add ddH2O.
Table 33: Destainer
Substance Concentration
EtOH 20%
Acetic acid 10%
Add ddH2O.
Western Blot Proteins in the SDS-PAGE were transferred onto a nitrocellulose membrane
(Amersham, Germany). In the module X Cell II Blot Module (Life Technologies, UK)
a stack of the membrane and the nitrocellulose membrane, embedded in two layers of
Whatman paper and sponges was set up and filled with Towbin bu er. The transfer was
carried out in 1 h with 25 V.
The membrane was blocked for 1 h in TBS-T with 2 % milk powder, washed three times
with TBS-T and incubated over night at 4°C with the primary antibody diluted in TBS-
T (6x-His Tag Monoclonal Antibody 1:1000 (4E3D10H2/E3, Thermo Fisher, Germany),
anti-CD9 1:500 (ab92726, Abcam, USA), anti-CD63 1:1000 (10628D, Thermo Fisher Sci-
entific, USA), anti-Alix 1:1000 (634502, BioLegend, USA), anti-GFP 1:500 (ab38689, Ab-
cam, USA), anti-AAV 1:1000 (60158, PROGEN Biotechnik, Germany)). The membrane
was washed three times with TBS-T and incubated for 1 h with the secondary antibody
1:10,000 in TBS-T (HRP-coupled goat anti-Mouse secondary antibody (Life Technologies,
UK), anti-rabbit (G-21234, Life Technologies, USA)). The membrane was again washed
before Luminata Forte Western HRP substrate (Merck Millipore, Germany) was added
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to the membrane and HRP activity was visualized with the chemiluminescence system.
Table 34: Towbin bu er
Substance Concentration
Tris 25 mM
Glycin 0.192 M
MeOH 20 %
Add ddH2O.
Table 35: TBS-T
Substance Concentration
Tris 50 mM
NaCl 150 mM
Tween-20 0.05 %
Add ddH2O. Adjust to pH 7.6.
2.4.6 Silver stain of SDS-PAGEs
Silver stain of SDS-PAGEs was performed after Heukeshoven and Dernick (1985). All
solutions were prepared with fresh purified water at the day of use. The SDS-PAGE was
incubated over night at 4°C in 150 ml fixation solution on a platform rocker. The gel was
then incubated for 2 h in 150 ml reduction solution and afterward washed three times for
20 min with ddH2O. 1 h incubation in 125 ml silver stain solution followed two wash steps
in ddH2O. 125 ml developer solution was added until a brownish precipitate was formed.
The gel incubated in 125 ml fresh developer until the aimed dying intensity was reached.
The dye-reaction was stopped with 125 ml of the 0.05 M glycine solution in ddH2O, which
was then removed in three washing steps.
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Table 36: Fixation
Substance Concentration
EtOH 30 %(v/v)
Acetic acid 10 %(v/v)
Add H2O.
Table 37: Reduction
Substance Concentration
C2H3NaO2 (water free) 0.5 M
Glutaraldehyde 0.5 %(v/v)
Na2S2O3*5H2O 0.2 %(v/v)
Add H2O.
Table 38: Silver stain
Substance Concentration
AgNO3 0.1 %(w/v)
Formaldehyde 0.02 %(v/v)
Add H2O.
Table 39: Developer
Substance Concentration
Na2CO3 2.5 %(w/v)
Formaldehyde 0.01 %(v/v)
Add H2O.
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2.5 Statistics and software
Statistics and graphical presentations were done with GraphPad Prism6 and R. Illus-
trations were done with ChemDraw Professional 15.1 or Microsoft PowerPoint. Plasmid
maps were generated with SerialCloner2-6.
2.6 Cortex injection and tissue staining of Macaca mulatta
Handling of the animals and experiments were performed in compliance with the guidelines
for the welfare of experimental animals issued by the European Communities Council Di-
rective (86/609/EEC) and the laws of the Federal Government of Germany. In accordance
with the German Protection of Animals Act (Tierschutzgesetz; TierSchG), all procedures
were approved by State authorities (LAVES) and the Animal Welfare O ce of University
Medical Center Göttingen, Germany.
The craniotomy and stereotactic virus injection in the cortex of an adult Macaca mulatta
was performed by Prof. Dr. Stefan Treue, Prof. Dr. Hansjörg Scherberger, Prof. Dr.
Alexander Gail, Dr. Michal Fortuna and Janina Huer (German Primate Center, Göttin-
gen). rAAV2/5-CaMKIIa-hChR2(H134R)-eYFP-WPRE (8.5x1012 vg/ml) (Viral Vector
Core, University of North Carolina (UNC), Chapel Hill, USA) and rAAV2/5-CaMKII-
eNpHR3.0-eYFP in 40 % iodixanol (7.8x108 vg/ml) were loaded into a hamilton syringe
and applied with 200 nl/min for 5 min (total 1 µl) per injection site in the ventral pre-
motor cortex and dorsal premotor cortex, respectively. Per injection site three deposits
in Z-plane were applied. The scull was closed with the bone flap.
The animal was euthanised 10 weeks after surgery and perfused with heparanized PBS
and afterwards with 4 % PFA in PBS.
The immunofluorescent stainings were performed by Dr. Michal Fortuna. The fron-
toparietal network was processed in 50 µm thick, free floating coronal slices and stained
with antibodies chicken anti GFP (GFP-1020, Aves Labs, USA), Mouse Anti-NeuN Anti-
body (MAB377, Merck Millipore, Germany), Alexa Fluor® 488 A niPure F(ab’)2 Frag-
ment Donkey Anti-Chicken IgY (IgG) (H+L) (Code: 703-546-155) and Alexa Fluor® 647
A niPure F(ab’)2 Fragment Donkey Anti-Mouse IgG (H+L) (Code: 715-606-150) and
the images taken with an Axio Imager M2 microscope (Zeiss, Germany).
This experiment is partially described for another evaluation purpose in the submitted
thesis from Huer (2018).
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2.7 Cochlea injection and tissue staining of mice
Handling of the animals and experiments were performed by Dr. Vladan Rankovic in com-
pliance with the guidelines for the welfare of experimental animals issued by the European
Communities Council Directive (86/609/EEC) and the laws of the Federal Government of
Germany. In accordance with the German Protection of Animals Act (Tierschutzgesetz;
TierSchG), all procedures were approved by State authorities (LAVES) and the Animal
Welfare O ce of University Medical Center Göttingen, Germany. Approximately 0.5 µl
virus (rAAV2/5- CAG-GFP and rAAV2/5-CaMKII-eNpHR3.0-eYFP) were injected in
the right cochleas of P6 C57 BL/6J mice through the round window membrane, whereas
the left cochleas were left uninjected and served as controls. The mice were euthanised 40
days after injection. Their embedded cochlea was sliced and stained against GFP/YFP
(chicken anti-GFP # ab13970, Abcam, UK; goat anti chicken 488 IgG (H+L) # A11039,
MoBiTec, Germany) for virus expression and against parvalbumin/calretinin (guinea pig
anti parvalbumin polyclonal # 195004, SYSY; rabbit anti calretinin CR 7697 # 7697,
Swant; goat-anti-guinie apig 568 # A11075, Life Technologies, UK; alexa fluor 633 goat
anti-rabbit IgG # A21070, Thermo Fisher, Germany) for neurons and the images taken
with an Axio Imager M2 microscope (Zeiss, Germany).
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Gene therapy is an emerging field in research and (pre-)clinics for the cure of various
diseases, which requires secure gene delivery tools and e cient gene expression.
The focus of this study lies on the delivery tools itself which can be used for any gene-
transfer approach. In particular, we concentrated on the delivery to neuronal cells with
the exemplary application of optogenetics which can be expanded to any other applica-
tion.
For the sake of simplicity, because several approaches were handled in parallel, the fol-
lowing chapters are arranged in the most logical order to understand and interpret the
results.
3.1 Standard rAAV production and evaluation
rAAVs´ production is simple, but its purification for in vivo application is still challenging.
This drawback is even shown by the fact that new protocols are continuously published,
indicating that no gold standard has yet been found. AAV5 is the most diverse serotype.
In this study it was used to set up a robust pipeline which allows a high standard pro-
duction and functional evaluation of rAAVs for in vivo use and which can be applied for
further serotypes. rAAVs are commonly produced in human cell lines by co-transfection
of the plasmids coding for the gene of interest which is located between the two ITR
sequences, and the genes which code for AAV capsid and packaging proteins. For rAAV5,
the vast majority of the virus is maintained within the cell and not released to the medium
(Vandenberghe et al., 2010). Therefore, we chose to purify rAAVs from the cells which
were harvested two days after transfection and subsequently lysed. The virus-containing
crude cell lysate was low-speed centrifuged to deplete the cell debris. This virus sample
can already be used for applications in vitro and ex vivo (see Figures 6, 15, 16, and 17).
Each rAAV serotype has a di erent ability to infect a variety of cell types. For being able
to reach a high transduction e ciency which also depends on the species, the target tissues
or cells, it requires the use of an application specific serotype and promotor. Therefore,
we produced five di erent serotypes (rAAV1, rAAV2, chimeric rAAV1/2, rAAV5, and
rAAV6). With the rationale to allow a transduction quantitation on the single cell level
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by microscopy or by flow cytometry, we delivered the fluorescent transgene GFP. The
GFP expression is driven by the constitutive CAG promotor (Hitoshi et al., 1991), the
two neuron-specific promotors calcium/calmodulin-dependent protein kinase II (CaMKII,
Mayford et al. (1996)) or human synapsin (hSyn, Li et al. (1993)).
As the total yield of a production might di er depending on the serotype, but might
include a constant e ort, we compared the transduction e ciency of equal amounts of
workflow preparations. Equal numbers of five di erent human cell lines (SKBR3, SH-
SY5Y, SW480, HEK, and HeLa) were transduced with the crude lysate. The percentage
of transduction events was determined via flow cytometry for GFP positive cells two days
post-transduction (Figure 6).
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Figure 6: Transduction of five human cell lines by five rAAV serotypes with three
promotors Equal amounts of workflow preparations of rAAV serotypes 1, 1/2, 2,
5 and 6 delivering the transgene for GFP were applied on human cell lines. The
transduction e cency was determined via flow cytometry analysis as the percentage
of GFP positive cells after 48 h. (A) Transduction e ciency with CAG promotor
driven expression. (B) Comparison of CAG, CaMKII and hSyn promotor strength
of five rAAV serotypes on HeLa cells.
rAAV serotypes 2 and 1/2 in combination with the CAG promotor were broadly e cient
on all five cell lines, whereas serotype 5 was least e cient. All serotypes performed best on
72
3 Results
HeLa cells, with a maximum of 94 % transduced cells for serotype 1/2 and a minimum of
11 % for serotype 5 (Figure 6A). SKBR3 was least e ciently transduced by all serotypes,
although serotypes 1 and 1/2 achieved at least 18% transduction.
Due to these findings, we chose the HeLa cell line for further analysis of rAAV perfor-
mance.
Next, we wanted to elucidate which of the commonly used promotors in optogenetic con-
structs (CaMKII and hSyn) leads to a detectable expression in HeLa cells (Fig. 6B). The
expression under the CAG promotor turned out to be the highest, with up to 94% in
combination with serotype 1/2. An exception was the serotype 2, where CaMKII was
slightly stronger than CAG. Comparable to the CAG promotor, CaMKII induced a suit-
able expression level, except for serotype 5. The hSyn promotor induced only the GFP
expression in a few cells, with a maximum of 4 % achieved for serotype 2. However, the
induction of the hSyn promotor was too low for subsequent analysis.
In conclusion, these data indicate that the highest transduction rates in cell culture can
be achieved with the serotypes 2 and 1/2 on Hela cells where constructs with the CAG
and the CaMKII promotor can be used. rAAV serotype 5 performed poorly in vitro and
requires an evaluation ex vivo or in vivo for applications with the CaMKII and hSyn
promotor (see 3.1.3).
3.1.1 Purification of standard rAAVs
Centrifugational purification yields a minor enrichment of rAAVs
The crude cell lysate needs further purification, to deplete cell-derived proteins and empty
viral particles and to concentrate the rAAV before it is utilised for in vivo applications.
As a putative time and cost saving purification method which can be performed in any lab
equipped with a tabletop centrifuge, we performed a stepwise centrifugation-based proto-
col. This protocol is performed in other groups to purify and to concentrate rAAVs for in
vivo experiments with rodents (Protocol from Alexandra Rupp, based on personal commu-
nication with Carola Gregor, Max-Planck-Institute for Biophysical Chemistry, Göttingen).
The virus-containing crude cell lysate was sequentially centrifuged as summarized in Fig-
ure 7 and the final pellet resuspended in PBS. To visualise cell-derived and viral proteins,
we loaded the samples on an SDS-PAGE and stained the proteins with coomassie. The
three viral capsid proteins VP1, VP2, and, VP3 have a size of approximately 87 kDa,
73 kDa, and 61 kDa, respectively. The SDS-PAGE only showed a minor depletion e ect
of non-viral proteins which is why the capsid proteins could not be identified. Next, to
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check for enrichment of functional viruses, we transduced equal amounts of HeLa cells
with equal volumes of the lysate, the supernatant, and the pellet and then determined
the percentage of transgene expressing cells (Figure 7C and D). The final pellet was re-
suspended in one-tenth of the crude cell lysate volume in PBS. However, the amount of
transduced cells increased only threefold and a remarkable number of the virus remained
in the supernatant.
In summary, the virus enrichment did not reach our expectations of a high-quality virus
that can be applied in vivo (for comparison see 3.1.2). Moreover, the coomassie stained
SDS-PAGE and the controls where we loaded the crude lysate with or without containing
the virus (not shown) indicated that the identification of rAAV capsid proteins in impure
samples requires detection by silver stain or Western Blot (see Figure 9).
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Figure 7: Sequential centrifugation protocol leads to a minor enrichment (A) Se-
quential centrifugation of crude lysate. (B) HeLa cells transduced with lysate, su-
pernatant, and pellet of the purification procedure. (C) Coomassie stained SDS-
PAGE of crude lysate purification steps. (D) TU/ml of crude lysate purification
steps determined by GFP expression.
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Density gradient based purification e ciently enriches rAAVs
Considering the di erent density of empty capsids and cell-derived proteins from the
genome-containing viral capsids, we performed an iodixanol density gradient to reduce
their amount more e ciently. The gradient consisted of four layers with iodixanol con-
centrations from 15% to 58%. The crude cell lysate was applied on top, and the protein
complexes separated during centrifugation. The gradient was harvested from top to bot-
tom in twenty-two 1 ml fractions (Figure 8A).
A first transduction test on Hela cells showed mentionable amounts of functional virus
in fractions 13 to 18 (data not shown), of which we furthermore determined the more
elaborate functional titer as well as the genomic titer. We applied serial dilutions of the
virus on HeLa cells and analysed them for transgene expression. The data of technical
triplicates were plotted over the applied vector genomes (vg), and a linear regression was
fitted to evaluate the concentration of transducing units (for illustration see Figure 22).
The genomic and functional titer correlated and had a maximum in fraction 15 with
5.46x108 vg/ml and 1.14x106 TU/ml.
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Figure 8: rAAV2/5-CAG-GFP disribution in iodixanol density gradient: genomic
and functional titer (A) Iodixanol density gradient structure with crude lysate on
the top and four phases with increasing iodixanol concentrations. The gradient is
harvested in 1 ml fractions from top to bottom. (B) Genomic and functional titer
of the gradient fractions 13-18. Transduction partially performed by Svenja Niehus.
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In the subsequent approach, we aimed to increase the titer of pure fractions and to ex-
change the iodixanol with a storage bu er for the rAAVs. Therefore, we dialysed the
samples against PBS-MK and concentrated the virus with centrifugational concentrators.
Equal volumes of dialysed and concentrated fractions 12-18 were then loaded on an SDS-
PAGE and we performed a sensitive silver stain of the proteins (Figure 9). A pure virus
sample only contains the three viral capsid proteins. In our purification, fractions 13 to
18 contained the three viral protein bands only, whereas fraction 12 showed additional
bands around 20 and 27 kDa. The titer of the fractions increased up to 1010 vg/ml.
Taken together, the iodixanol gradient fractions 13 to 18 contained functional and pure
viruses and were therefore also harvested in subsequent purification rounds. Aiming to
increase the titer, we also pooled them before dialysis.
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rAAV column purification
With the aim of discriminating further empty rAAV5 capsids and cell-derived proteins,
we additionally tested several FPLC based protocols which were also described to be
applicable for the crude cell lysate. The samples which we loaded on the columns came
directly from the iodixanol gradient or were previously dialysed as summarized (Table 40).
None of the column and bu er conditions led to a detectable virus-derived peak in the
chromatograms and the viral genomes were mainly found in the flow through.
Faced with the possibility that a higher number of viruses were necessary to set up the
FPLC protocol and our resources were limited, we considered the previously described
purification in our production range as superior.
Table 40: rAAV column purification
Column Sample Citation
HiTrapTM Con A 4B dialysed iodixanol gradient
fractions
Manufacturer´s protocol (GE
Healthcare)
PD10 desalting column iodixanol gradient fractions Manufacturer´s protocol (GE
Healthcare)
MonoQ 5/50GL gradient fraction and dialysed
gradient fraction
Zolotukhin (2002)
HiTrap Heparin HP gradient fraction and dialysed
gradient fraction
Zolotukhin (1999)
3.1.2 Quality control comparison with reference in vivo quality viruses
Virus titer and functionality
To yield a high titer virus the iodixanol fractions 13-18 were dialysed and concentrated.
Thereby the iodixanol was exchanged to PBS-MK bu er. The PBS-MK bu er allows the
storage without virus precipitation, reduces the viscosity of the sample and is suitable
for in vivo application. Next, we compared the virus titers and functionality with the
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reference virus.
We quantified the genomic titer by real-time PCR. However, it was demonstrated that the
results of the real-time PCR depended on the location of the amplified sequence (Werling
et al., 2015), and there is no standard for this method yet. Therefore, we determined the
titers of three reference viruses with our real-time PCR setup and compared them with
their given titers.
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Figure 10: Genomic and functional titer of reference and self-produced viruses (A)
Comparison of three reference viruses with given and measured titer with a self-
produced rAAV2/5-CAG-GFP. (B) Genomic and functional titer of comparable
rAAVs from the manufacturer and self-production. Error bars in measured genomic
titers indicate standard deviation of triplicate measurements.
The three reference viruses had a given genomic titer of 1012 vg/ml. Measured with our
real-time PCR setup, the titer was approximately two magnitudes lower (Figure 10). Our
self-produced rAAV2/5-CAG-GFP with a titer of 1011 vg/ml is thereby one magnitude
higher compared to the reference viruses.
Next, we compared the functional titer. For that purpose, we used the most suitable and
available reference, which was rAAV2/5-SSpEMBOL-CBA-GFP. It also contains a consti-
tutive promotor for GFP expression but lacks the WPRE sequence which prevented the
quantification of the genomic titer. The self-produced virus had a titer of 5x106 TU/ml
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and the reference virus 3x107 TU/ml (Figure 10B).
The genomic and the functional titer get better the higher they are, whereas the ratio of
vg/TU describes the functionality of a viral batch and a lower ratio characterises a higher
functional virus. Compared with the given titer of the reference virus, the self-produced
virus is one magnitude lower, meaning higher functionality. Assuming the genomic titer
of the reference to be up to two magnitudes lower, this ratio reverses. Thus there is no
absolute comparison possible we can finally conclude to have a virus in the same range of
functionality.
In short, we set up the quantification of the genomic and the functional titer of rAAVs
and concluded that we produced a functional virus with a high genomic titer.
Silver stain for the visualisation of proteins
After checking the titer and functionality of our virus production, we compared its pu-
rity with the reference virus. For that purpose, equal sample volumes were loaded on an
SDS-PAGE and proteins were visualised with a silver stain (Figure 11).
The capsid proteins could thereby be visualized with a minimum of 7.5x109 vg per
lane (data not shown). Only the expected three bands in the size of the viral cap-
sid proteins were visible for the reference virus (Figure 11A). The self-produced high
titer viruses rAAV2/5-CAG-GFP (3x1011 vg/m) and rAAV2/5-CaMKII-eNpHR3.0-eYFP
(4x1011 vg/m) had additional bands (Figure 11B). The first had one protein band of ap-
proximately 20 kDa (indicated by the arrow) whereas the other had several additional
bands.
Despite the harvest of the previously selected fractions 13 to 18, not all co-purified proteins
could be depleted. The enrichment of them might correlate with the volume of crude cell
lysate that was loaded on the iodixanol gradients. In spite of everything, we showed that
our purification could greatly enrich the virus with only minor impurities which need to
be identified.
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Figure 11: Silver stained SDS-PAGES for purity evaluation of rAAV samples (A)
Reference virus. (B) High titer viruses from own productions. Arrow indicates the
co-purified protein of approximately 20 kDa. M: Marker
Electron microscopy for di erentiation between full and empty capsids
Electron microscopy of negative stained rAAV samples was utilised to quantify the dis-
tribution of filled and empty capsids (Figure 12). Each rAAV production yields capsids
which are not successfully loaded with a viral genome and these empty capsids cannot be
completely depleted by the purification. That is why a high percentage of filled capsids
is another quality feature of a purification.
Based on the low number of viral particles on our micrographs we give a rough calculation
of the distribution of empty and filled particles which is su cient for our purpose (Figure
12). 37 % of the capsids of the reference virus (rAAV2/5-SSpEMBOL-CBA-GFP) were
filled and 39 % of rAAV2/5-CAG-GFP and 41 % of rAAV2/5-CaMKII-eNpHR3.0-eYFP
from the own production (see also Figure 11). Additionally to the viral capsids with
approximately 25 nm in diameter (Walters et al., 2004), donut shaped particles with ap-
proximately 10 nm in diameter were visible in both own productions (indicated by the
arrow).
Taken together, the viral samples only di er a little compared to the percentage of filled
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particles, and we can conclude that they, based on this, have the same quality. However,
the self-produced viruses bear a co-purified, small protein complex.
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Figure 12: Visualisation of rAAV capsids by electron microscopy rAAV samples were
negatively stained and fixed via UV-light exposure. All samples bear round par-
ticles of 25 nm in size, which correspond to genome filled (white arrow head) and
empty (black arrow head) rAAV capsids. Micrographs of self-produced rAAVs show
additional particles with around 10 nm in diameter (arrow).
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Mass spectrometry identifies co-purified proteins
Silver stain and electron microscopy indicated a co-purified impurity which we charac-
terised as a donut-shaped protein complex consisting of around 20 kDa proteins. Using
mass spectrometry, we identified the proteins in the gel piece of rAAV2/5-CAG-GFP,
located at the height of about 20 kDa.
Mass spectrometry analysis was performed in Prof. Dr. Henning Urlaub´s lab for bioan-
alytical mass spectrometry (Max-Planck-Institute for Biophysical Chemistry, Göttingen)
and the results BLASTed against all entries in UniProt (Table 45). The top ten of a total
134 hits are summarized in Table 41, with the three most abundant proteins: ferritin light
chain, trypsin, and ferritin heavy chain.
Table 41: Top ten mass spectrometry hits
Number Identified proteins Molecular
weight
Total of
spectra
1 Ferritin light chain (Homo sapiens) 20 kDa 0.44 %
2 Trypsin (Sus scrofa) 24 kDa 0.37 %
3 Ferritin heavy chain (Homo sapiens) 21 kDa 0.33 %
4 Keratin type II cytoskeletal 1 (Homo sapiens) 66 kDa 0.19 %
5 Keratin type II cytoskeletal 2 epidermal (Homo sapiens) 65 kDa 0.13 %
6 Keratin type I cytoskeletal 10 (Homo sapiens) 59 kDa 0.12 %
7 Keratin type I cytoskeletal 9 (Homo sapiens) 62 kDa 0.089 %
8 Proteasome subunit beta type-5 (Homo sapiens) 28 kDa 0.089 %
9 Ferritin light chain (Bos taurus) 20 kDa 0.059 %
10 Tubulin beta-4 chain (Xenopus laevis) 50 kDa 0.049 %
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Considering the molecular weight and shape of the impurity and because keratin and
trypsin are known bias in mass spectrometry, we conclude that the co-purified protein in
our viral samples is ferritin.
Genetic toolbox for straightforward expression construct generation
To provide a straightforward and quick clonation strategy, we generated a genetic tool-
box inserting optimised restriction sites in rAAV plasmids. Thereby 80 combinations of
promotors, opsins, and reporter genes in an rAAV2 plasmid backbone are possible, and
further genes can easily be included (Table 42 and 43, supplements 5.1.1). It even allows
400 combination possibilities including the five used rAAV serotypes in this study.
Like most of the rAAV plasmids, the plasmid contains the woodchuck hepatitis virus
post-transcriptional regulatory element (WPRE) between the reporter gene and the ter-
minator (Wang et al., 2016).
All plasmids were checked for functionality via lipotransfection in HEK or HeLa cell lines
and microscopic detection of reporter gene expression (data not shown).
Additionally to the rAAV production, the toolbox simplifies the production of lentiviruses
and expression cassettes for VLPs as well and thereby enables an unbiased comparison of
transduction e ciencies.
pAAV
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Figure 13: Schematic rAAV genetic toolbox The toolbox allows with four restriction sites
(MluI, BamHI, NdeI and HindIII) 80 combination possibilities of promotors, opsins
and reportergenes in an rAAV2 plasmid backbone.
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Table 42: rAAV plasmids from Addgene
Plasmid # Name Source, Addgene #
1 pAAV-CAG-hChR2(H134R)-
tdTomato
a gift from Karel Svoboda, 28017
2 pAAV-CAG-GFP a gift from Karel Svoboda, 28014
3 pAAV-Ef1a-DIO eNpHR-eYFP a gift from Karl Deisseroth, 26966
4 pAAV-CaMKII-ArchT-GFP a gift from Edward Boyden, 37807
5 pAAV-CaMKIIa-eArch3.0-eYFP a gift from Karl Deisseroth, 35516
6 pAAV-hSyn-hChR2(H134R)-
mCherry
a gift from Karl Deisseroth, 26976
7 pAAV-CaMKIIa-eNpHR3.0-eYFP a gift from Karl Deisseroth, 26971
86
3 Results
Table 43: Modified rAAV plasmids
Plasmid # Name Modification
8 pAAV-CaMKII-GFP ligation of #2 & #5
9 pAAV-hSyn-GFP ligation of #2 & #6
10 pAAV-Ef1a-GFP ligation of #3 & #9
11 pAAV-CaMKIIa-eArch3.0-NdeI-
eYFP
#5 with NdeI insertion
12 pAAV-CaMKII-ArchT-NdeI-GFP #4 with NdeI insertion
13 pAAV-hSyn-hChR2(H134R)-NdeI-
mCherry
#6 with NdeI insertion
14 pAAV-CaMKIIa-eNpHR3.0-NdeI-
eYFP
#7 with NdeI insertion
15 pAAV-CaMKII-eNpHR3.0-GFP ligation of #12 & #14
16 pAAV-CaMKIIa-hChR2(H134R)-
mCherry
ligation of #6 & #7
17 pAAV-CaMKII-Jaws-GFP ligation of #5 & PCR of UNC
rAAV2/5-CaMKII-JawsKGC-GFP-
ER2
Quick readout of opsin functionality in HeLa cells
As a proof of concept we wanted to demonstrate that the produced virus drives a func-
tional opsin expression and enables the generation of illumination evoked photocurrents.
We transduced HeLa cells with rAAV2/5-hChR2(H134R)-tdTomato and four days after
transduction voltage clamp in combination with a 500 µs light pulse at 488 nm was per-
formed to record photo currents. The light stimulation did cause no photo currents in
non-transduced cells, whereas photo currents were measured in a transduced cell, identi-
fied by reporter gene expression (Figure 14).
This result confirms that we produced a functional virus which can be utilized for opto-
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gentic experiments. We furthermore point out that viruses with constructs for optogentics
expressing in HeLa cells can be tested for their opsin functionality in an easy set up.
500 ms
 100 pA 
500 ms
 100 pA 
500 ms
 100 pA 
500 ms
 100 pA 
control
rAAV2/5-CAG-hChR2(H134R)-tdTomato
injected
a
b
100 µm
Merged channels
phase and red
Figure 14: Illumination evoked response of light gated channelrhodopsin (A) Volt-
age clamp of a non-transduced HeLa cell with light stimulation. (B) HeLa cell
transduced with crude lysate of rAAV2/5-CAG-hChR2(H134R)-tdTomato shows
reporter gene expression. Photocurrent was recorded after a 500 µs pulse with 5%
laser intensity at 488 nm. Scale bar indicates the recorded current (vertical) and
the time (horizontal). Experiment performed together with Markus Stahlberg.
Summary of rAAV production, purification and quality control
We provide a workflow for rAAV production that is independent of the serotype. We
yielded a high-titer, functional virus in a good purity grade via depletion of cell-derived
proteins by density gradient purification, re-bu ering and concentration. The only co-
purified protein in our best purification can be based on its molecular weight, appearance
in electron microscopy, and mass spectrometry analysis identified as ferritin.
Additionally, we characterised five rAAV serotypes for their transduction profile on a
variety of human cell lines. With our genetic toolbox, we provide a straightforward way
for the clonation of expression constructs for rAAVs, lentiviruses and VLPs. These can
be tested in a patch clamp setup, depending on their expression in HeLa cells.
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3.1.3 Ex vivo and in vivo applications of rAAVs
rAAVs transduce human MSCs and cortex tissue of murine and non-human primate origin
Additionally to the production of rAAVs we wanted to elucidate to which extent the virus
can be tested ex vivo before applying it in vivo.
Mesenchymal stem cells (MSCs) - In order to characterise the rAAV serotypes for their
ability to transduce primary human cells, we applied them on MSCs which had been de-
rived from the Warton´s jelly of the umbilical cord (Figure 15A). Equal numbers of cells
derived from three donors (#83 female, #97 female, and #108 male) were transduced
with equal amounts of workflow preparations and analysed for GFP-transgene expression
after seven days (similar to 3.1).
5
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rAAV serotype
1/2 2 5 61
%
 G
FP
+  c
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s
#83
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rAAV1/2-CAG-GFPcontrol
phase                              GFP phase                                GFP
a
b
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200 µm
Figure 15: Human MSCs are susceptible to five rAAV serotypes with di erent pref-
erence (A) Equal amounts of workflow preparations of rAAV serotypes 1, 1/2, 2,
5, and 6 delivering the transgene for GFP and the CAG promotor were applied on
human MSCs. The percentage of transduced cells was determined via flow cytom-
etry 7 days after transduction. (B) Mock transduced and rAAV2-1/2-CAG-GFP
transduced MSCs of donor #108 which showed the highest transduction.
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Based on the percentage of the GFP-expressing cells, the susceptibility of the MSCs briefly
varied for the di erent serotypes, as well as it varied for rAAVs in general between the
donors. The MSCs from donor #97 were well susceptible to all five serotypes within a
range of 10 - 15% GFP positive cells and with rAAV 6 being superior. More interest-
ingly, #83´s MSCs were not susceptible to serotype 1 but well transduced with serotype
2. The susceptibility of MSCs from donor #108 highly varied in particular, being most
susceptible to serotype 1/2 (Fig. 15B).
In conclusion, cultivated MSCs derived from the Warton´s jelly of the umbilical cord are
well susceptible for rAAVs but have a serotype preference depending on the donor.
Dissociated cortex cultures - In the next step we elucidated the serotypes´ performance on
dissociated cortex cultures from the Wistar rat. These cultures contained a mixed popu-
lation of neurons and glia cells. Similar to the test of serotypes and promotors on human
cell lines and MSCs, the cultures were transduced with equal amounts of virus-containing
crude lysates. The transduced cultures were observed by fluorescence microscopy for the
expression onset of GFP and micrographs were taken on day 6 in vitro (Figure 16).
rAAV serotype 1/2 in combination with the CAG and the CaMKII promotor showed
an expression onset just one day after transduction. But during the observation period
there was no expression visible for serotype 2, and serotype 5 combined with the hSyn
promotor. More interestingly, most viruses led to an expression onset on day 5 in vitro.
In general, rAAV5 only transduced a few cells compared to rAAV1/2 and rAAV1 which
were the most e cient viruses. Moreover, we exclusively observed expression in glia cells
for serotype 5 independent of the promotor. Expression under the hSyn promotor was
exclusively detected in neurons in general, whereas it was also found in glial cells for the
CAG and the CaMKII promotor (morphological cell type identification).
In summary, all rAAV serotypes except rAAV2 transduced dissociated cortex cultures
from the Wistar rat. More importantly, no expression in neurons was visible after trans-
duction of rAAV5 which leads us to the conclusion that it might be due to its overall
shown low transduction e ciency.
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                    Serotype       
        Promotor
CAG
CaMKII
hSyn
200 µm
1                              ½                                5                               6      
transduction
div 1            2             3                                            4                                          5                                             6
rAAV2/(1/2)-CAG-GFP
rAAV2/(1/2)-CaMKII-GFP
rAAV2/1-CAG-GFP
rAAV2/1-CaMKII-GFP
rAAV2/1-hSyn-GFP
rAAV2/5-CaMKII-GFP
rAAV2/6-CAG-GFP
rAAV2/6-CaMKII-GFP
rAAV2/6-hSyn-GFP
rAAV2/5-CAG-GFP
rAAV2/(1/2)-hSyn-GFP
Promotor
CA
CaMKII
hSyn
Serotype
1 1/2 5 6
Figure 16: Expression of rAAVs in dissociated Wistar rat cortex cultures Dissociated
rat cortex cultures were transduced with equal amounts of crude cell lysate of rAAV
serotypes 1, 2, 1/2, 5, and 6 harboring an expression construct with CAG, CaMKII
or hSyn promotor and GFP-transgene on day 3 in vitro (div). The vectors are
itemized at the day of their first visible GFP expression. Micrographs were taken
at day 6 in vitro.
Acute cortex slices - In the next step to further approach the in vivo model, we tested the
transduction ability of rAAV serotype 5 on acute cortex slices of several species. We chose
CNS derived from the E19 Wistar rat, the adult Macaca fascisularis, the adult Macaca
mulatta, and from newborn Callithrix jacchus.
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We applied several expression constructs on the cortex slices and obtained in our study
di ering expression onsets in repeated experiments. In general, constructs with an opsin
additionally to the reporter gene had a slower expression onset or did not lead to an ex-
pression until the cortex slice cells died. In the tissue of the non-human primates no other
constructs than rAAV2/5-CAG-GFP led to an expression. Furthermore, no expression
was visible on the material from Macaca mulatta before the cortex cells died.
AAV2/5-CaMKII-ArchT-GFP
200 µm
AAV2/5-CAG-hChR2(H143R)-
tdTomato
AAV2/5-CAG-GFP AAV2/5-CAG-GFP
Wistar rat Wistar rat 
Macaca fascicularis Callithrix jacchus
r AV2/5 G-GFP rAAV2/5- -GFP
rAAV2/5-CaMKII-ArchT-GFP rAAV2/5-CAG-hChR2(H134R)-tdTomato
Figure 17: Expression of rAAV5 constructs in acute cortex slices of Wistar rat and
non-human primate origin rAAV5 vectors were applied on acute cortex slices.
The expression of the reporter gene could be detected on cultures of the Wistar rat,
Macaca fascicularis and Callithrix jacchus.
From this data we conclude, that our self-produced rAAVs of the serotype 5 transduce
cortex slices of rodent and non-human primate origin. But because the outcome of the
experiments highly varied and the expression of opsins was uncertain, we conclude that
rAAVs of the serotype 5 for opsin delivery have to be functionally tested in brain models
or in vivo. Additionally, these data indicate a correlation of the culture viability and the
age of the animal. We also conclude that CNS from adult non-human primates can be
utilised for the culture of acute cortex slices, but have a limited usability for experiments
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which require a longer time range of several days.
In vivo rAAV5 functionality
rAAV5 transduces supporting cells in the cochlea of mice
Having shown that the rAAV serotype 5 can only be very limitedly tested ex vivo (see
3.1.3), we then evaluated its functionality in vivo. Approximately 0.5 µl virus (rAAV2/5-
CAG-GFP and rAAV2/5-CaMKII-eNpHR3.0-eYFP, for further information see 3.1.2)
were injected in the right cochleas of P6 C57 BL/6J mice through the round window
membrane, whereas the left cochleas were left uninjected and served as controls. The
mice were euthanised 40 days after injection. Their cochlea was sliced and stained against
GFP/YFP for virus expression and against parvalbumin/calretinin for neurons (Figure
18).
The stainings visualised supporting cells (arrow), inner hair cells (asterisk) and spiral gan-
glion neurons (arrowhead). The whole tissue had a low fluorescence in the green channel.
However, several supporting cells in both injected cochleas had an increased fluorescence.
To subtract the unspecific fluorescence of the tissue and evaluate the di erence of the
GFP intensity, we measured the GFP intensity of spiral ganglion neuron areas and sup-
porting cell areas of the control and the injected cochleas (Figure 18C and supplemental
Figure 34). We compared the di erences of the injected and non-injected animals in the
fluorescence intensity of the spiral ganglion neurons with the di erences in fluorescence
intensity of the supporting cells. The data indicated a fluorescence above the background
fluorescence for the suppoting cells for both viruses, with rAAV2/5-CAG-GFP driving a
higher GFP expression than rAAV2/5-CaMKII-eNpHR3.0-eYFP.
Taken together, both viruses lead to transgene expression in several supporting cells after
injection in the mice´s cochleas.
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Figure 18: Expression of rAAV5 in the mouse cochlea rAAV2/5-CAG-GFP (A) and
rAAV2/5-CaMKII-eNpHR3.0-eYFP (B) were injected in the right cochleas of mice,
and the left uninjected cochleas served as controls. The cochleas were subsequently
stained against GFP (green), parvalbumin (red) and calretinin (blue). Supporting
cells (arrow), inner hair cells (asterisk) and spiral ganglion neurons (arrowhead).
Scale bar 100 µm. (C) GFP/ YFP intensity measurement. The injection of the
mice and immunofluorescence staining was performed by Vladan Rankovic and
Daniela Gerke (University Medical Center, Göttingen), and micrographs were taken
together.
rAAV5 expression in the cortex of Macaca mulatta
The reference virus rAAV2/5-CaMKIIa-hChR2(H134R)-eYFP-WPRE (8.5x1012 vg/ml)
was injected in the ventral premotor cortex (PMV) and the self-produced rAAV2/5-
CaMKII-eNpHR3.0-eYFP (in 40% iodixanol, 7.8x108 vg/ml) in the dorsal premotor cortex
(PMD), respectively, of a Macaca mulatta. The animal was euthanised ten weeks after
injection and the brain regions were processed for immunofluorescence staining with an-
tibodies against NeuN for neurons and against eYFP to identify fusionprotein-expressing
cells (Figure 19B and C) (see 2.6 for experimenters).
The two, approximately 5 mm deep injection tracks of the reference virus were surrounded
by cell bodies of eYFP expressing cells in a radius of approximately 1.5 mm. In contrast,
no injection tracks were detected within the rAAV2/5-CaMKII-eNpHR3.0-eYFP injection
site. But it appeared as a wedge-shaped and sharply demarcated area of lower background
fluorescence and a reduced number of NeuN positive cells in an area of approximately
2 mm in diameter.
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b                                                          c
2 mm 2 mm
a                                                          
PMD                                                          
PMV                                                          
Figure 19: Immunofluorescence stainings of rAAV5 injected Macaca mulatta cortex
(A) Schema of cortex regions PMV and PMD (B) Ventral pre-motor cortex injec-
tion site of rAAV2/5-CaMKII-eNpHR3.0-eYFP (C) Frontal eye field injection site
of rAAV2/5-CaMKIIa-hChR2(H134R)-eYFP-WPRE. Slices were stained for NeuN
(red) and eYFP (green). This experiment and micrograph B are partially as well
described in Huer (2018).
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3.2 CD9GFP over-expression for a higher yield of exo-AAV1
This section´s aim was to elucidate the impact of an increased exosome release by CD9GFP
over-expression of rAAV producer cells on the yield and e ciency of exo-AAVs, which had
been harvested from the cell culture media. As a proof of concept we demonstrated that
during rAAV1 production the exosome and exo-AAV1 yield increased and additionally we
gained more e cient exo-AAVs. Unlike rAAV1, which besides had also been used in the
previously published studies on exo-AAVs (for details see 1.2.1), rAAV5 is not e ciently
released in the media. Therefore we chose the first for this study.
CD9 is a well known exosomal marker. In a publication, in which I am contributing
author, we recently demonstrated that its over-expression boosts the exosome production
in several human cell lines and additionally increases the infectivity of lentiviruses (see
supplemental 5.5 and Böker et al. (2017)).
To perform standard rAAV and exo-AAV production under boosted exosome conditions,
HEK-AAV producer cells were transduced with lentiviruses (LV-CD9GFP-VSV-G) for
CD9GFP over-expression. The cells were tracked by flow cytometry analysis and con-
sidered useful for rAAV production when at least 80% of the cells were GFP positive.
The CD9GFP expression was also visible in fluorescence microscopy and predominantly
localised in cell membranes.
The rAAVs were produced by the standard transfection procedure with pDP1rs and
pAAV-CAG-GFP. Subsequently, standard rAAVs were harvested from the cell lysate as
previously described, whereas exo-AAVs were harvested by sequential centrifugation steps
of the media (Figure 20).
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> 80% CD9GFP+ cells
rAAV1 production in HEK-AAV-CD9GFP cells
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Figure 20: Overview of HEK-AAV-CD9GFP cell production and standard and exo-
AAV harvest (A) HEK-AAV cells were transduced with LV-CD9GFP-VSV-G to
gain CD9GFP over-expression. The transgene cells were used for rAAV production
when at least 80% were determined to be CD9GFP positive by flow cytometry
analysis (B). rAAV production requires the transfection of the genetic construct
and the helper plasmid (pDP1rs). The standard rAAVs were harvested from the cell
lysate whereas exo-AAVs were harvested from the cell culture media via sequential
centrifugation. Scale bar 200 µm. Creative commons license CC BY-NC-ND 4.0,
modified from Schiller et al. (2018).
3.2.1 CD9GFP over-expression boosts exosome release in culture media
Our first aim was to a rm whether recombinant CD9GFP over-expressing HEK-AAV cells
have an increased exosome secretion as we similarly published for five other human cell
lines (see supplemental 5.5 and Böker et al. (2017)).
We firstly harvested vesicles of the media from wild type (HEK-AAV) and CD9GFP over-
expressing cells via polyethylene glycol (PEG) precipitation and secondly via the exo-AAV
purfication procedure. The concentration and size distribution of extracellular vesicles was
determined by nanoparticle tracking analysis (NTA) (Figure 21).
98
3 Results
The over-expression led to a significantly increased amount of PEG-precipitated vesicles
(1.96 times) with a mean size reduced from 210 nm to 184 nm. Thereby, the exosome
concentration (30-100 nm) in the media of over-expressing cells significantly increased
3.75 times as much.
Next, we elucidated whether the pellets of the exo-AAV harvesting procedure (20k and
100k) from wild type and over-expressing cells di ered in the vesicle distribution. To
have comparable cell physiological conditions, we mimicked the rAAV production con-
ditions by the transfection of pAAV-CAG-GFP. The conditioned media was processed
according to the exo-AAV harvesting protocol. Additionally, vesicles from the media and
supernatant were harvested by PEG precipitation because the vesicle concentration for a
direct analysis by NTA was too low. Being as reproducible as during PEG precipitation,
the over-expressing cells had the similar trend in exosome concentration for all pellets.
Especially the 100k pellet showed a higher proportional increase of exosomes with 5.75
times of the wild-type (Figure 21D). The profile of the vesicle size distribution in the 100k
pellets showed enrichment of vesicles in exosome size, whereas the 20k pellets and the su-
pernatants included more bigger vesicles up to over 600 nm (Figure 21E with exemplary
profiles for HEK-AAV-CD9GFP cells).
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3 Results
We verified the abundance of exosomes and CD9GFP-positive exosomes for the transgene
cells and rAAVs in the 20k and 100k pellets via Western Blot with antibodies against the
AAV capsid proteins, GFP and the exosomal markers (hAlix, CD9, and CD63) (Supple-
mental Figure 36).
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Figure 21: CD9GFP over-expression in HEK-AAV cells influences the vesicle content
in the media and the samples during exo-AAV harvesting procedure NTA
of PEG precipitated extracellular vesicles of CD9GFP over-expressing HEK-AAV cell
media showed a significantly increased amount of vesicles compared to wild type
cells (A), which were reduced in mean size (B) and had an increased amount of
vesicles in the size range of exosomes (30-100 nm) (C). (A, B and C) Samples
of biological triplicates were measured in technical triplicates. Significance was
tested via unpaired t-test for normally distributed data (B) and via Mann-Whitney
test for non-normal distributed data (A and C). Error bars indicate the standard
deviation, * P< 0.05, ** P<0.01. (D) The exosome amount during mimicked exo-
AAV harvesting procedure was in each step higher for the CD9GFP over-expressing
cells. (E) Exemplary size distribution profile of vesicles in the 20 k x g pellet, 100k
x g pellet, and remaining supernatant of CD9GFP over-expressing cells. Creative
commons license CC BY-NC-ND 4.0, modified from Schiller et al. (2018).
3.2.2 CD9GFP over-expression yields more e cient and increased amounts of
exo-AAVs
Having set up the exo-AAV production in wild type and CD9GFP over-expressing cells
and having demonstrated that the latter had an increased number of exosomes in the
100
3 Results
100 k x g pellet, we elucidated whether this increased release of exosomes causes a higher
amount and/or more functional exo-AAVs as well. Therefore, we quantified the genomic
titer by real-time PCR and the functional titer by flow cytometry analysis (Figure 22A).
At first, we observed no significant di erence in the genomic titers for both cell types in
any of the purification steps (Figure 22B).
For determining the functional titer, we secondly applied serial dilutions of the exo-AAV1
media and 100k pellet on HEK cells and analysed them for GFP expression. We plotted
the data of technical triplicates over the applied vector genomes (vg) and fitted a linear re-
gression (Figure 22B and Supplementary Figure 36). The slopes from the regression lines
for exo-AAVs and exo-AAV-CD9GFP significantly di ered, meaning that the exo-AAVs
from the over-expression cells were more e cient. Besides, we disproved in a control ex-
periment that the application of CD9GFP exosomes alone leads to GFP positive HEK cells.
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Figure 22: Enhanced transduction e ciency of exo-AAV1-CD9GFP (A) Method di-
agram of rAAV titration. HEK cells were transduced with a dilution series of
exo-AAV1 and exo-AAV1-CD9GFP and the number of CD9GFP expressing cells was
determined by flow cytometry analysis. The transducing units are plotted over the
applied vector genomes. Standard deviations of technical triplicates are shown by
the error bars. Linear regression lines (red and blue) were fitted and the P-value
(two-tailed) calculated to test whether the slopes are significantly di erent. (B) Ge-
nomic titer of three exo-AAV production rounds. Mean and error bars indicating
the standard deviation. (C) An exemplary plot for 100k pellet exo-AAVs.Creative
commons license CC BY-NC-ND 4.0, modified from Schiller et al. (2018).
The quotient of vg/TU characterises the e ciency of a virus, with a lower quotient in-
dicating a higher e ciency. Exo-AAV1-CD9GFPs were 26% ± 4.9% (mean±SD) more
e cient than the wild-type exo-AAV1s in independent biological triplicates. The media,
which contains a mixed population of standard and exo-AAVs, showed a smaller but also
significant boosting e ect of around 7% (Table 44).
It is important to point out, that the same genomic titer of viruses derived from CD9GFP
over-expressing cells transduced a higher amount of cells.
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Table 44: Ratio of vector genomes per transducing units for 100k pellet and media
Fraction
vg/TU % exo-AV-CD9GFP
e ciencyexo-AAV1 exo-AAV1-CD9GFP
100k pellet
1131 838 +26
2894 1968 +32
4699 3743 +20
Media 811 759 +6
Having observed that exo-AAV1-CD9GFP was up to 32% more e cient, we wanted to
elucidate whether this was the reason of a higher number of exosome-bound rAAVs due
to the higher number of released exosomes. We used an iodixanol density gradient to
separate vesicle-bound rAAVs from standard rAAVs.
Standard rAAV1, as well as exo-AAVs from wild-type and over-expressing cells, were
subjected to the gradient, ranging from 6 to 60 % iodixanol. After centrifugational sepa-
ration, we harvested 18 fractions of 1 ml (Figure 22A). The genomic titer of the fractions
was quantified and plotted as the percentage of total genomic copies (Figure 22B). The
standard vector served as our control to categorise the rAAVs together with the published
distribution of exosomes and exo-AAVs in two fractions (György et al., 2014; Cantin et al.,
2008). The standard rAAVs migrated to high-density fractions and exosome-bound rAAVs
to low-density fractions (indicated in figure 22A).
As expected from previous findings (see Figure 8), we mainly recovered standard rAAV1
(98.5%) in the high density fractions (14-18). Whereas exo-AAV1 migrated in low-density
fractions (4-13) with 29.25%, and exo-AAV1-CD9GFP with 47.66% which is around 39%
more. For all samples a rather negligible less than 1% remained in the lowest-density
fractions (1-3) and was not further evaluated.
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Figure 23: Exo-AAV1-CD9GFP enriched in lower-density fractions (A) Schema of the
iodixanol gradient with indicated fractions to which exosomes (Cantin et al., 2008),
exo-AAVs (György et al., 2014) and standard rAAVs are expected to migrate. (B)
Standard rAAVs and exo-AAVs from wild type and CD9GFP over-expressing cell
lines were loaded onto a gradient and fractions were analysed after centrifugation
for vector genomes. (C) % of total vector genomes categorised for fractions 1-3, 4-
13, and 14-18. Creative commons license CC BY-NC-ND 4.0, modified from Schiller
et al. (2018).
To sum up, we proved that CD9GFP over-expressing HEK-AAV cells produced a higher
amount of exosomes and we found out that exo-AAVs produced in these cells were 26% ±
4.9% (mean±SD) more e cient, compared to the production in wild type cells. Addition-
ally, these exo-AAV1-CD9GFP samples contained 39% more exosome-bound AAVs. These
results indicate that the higher transduction e ciency of exo-AAV1s from CD9GFP over-
expressing cells is due to the increased amount of rAAVs which are exosome-associated.
3.2.3 Exo-AAV serotypes 1 and 6 transduce mesenchymal stem cells
We further wanted to elucidate the performance of exo-AAVs from wild type and CD9GFP
over-expressing producer cells on primary cells. Therefore we applied the same number
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of genomic copies from exo-AAVs of serotype 1 and 6 on MSCs from the donors #83 and
#97. We determined the percentage of the GFP transgene expressing cells (under the
CAG promotor) by flow cytometry analysis one week after transduction.
The two donors had a di erent susceptibility for the exo-AAVs, whereas donor #97 was
more susceptible in general. Exo-AAVs of the serotype 6 led to a higher transduction than
exo-AAVs of serotype 1. Exo-AAV6-CD9GFP was slightly more e cient than exo-AAV6
on donor #83, whereas the exo-AAVs from the wild type cell line transduced more cells in
the other experiments. We observed no expression for exo-AAV1-CD9GFP with donor #97.
Taken together, the exo-AAVs had a di erent performance on MSCs, which depended on
their serotype. And neither the CD9GFP positive nor the CD9GFP negative exo-AAVs had
a generally higher transduction e ciency.
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Figure 24: Exo-AAV and exo-AAV-CD9GFP of serotypes 1 and 6 transduce mes-
enchymal stem cells Mesenchymal stem cells from donor #83 and #97 were
transduced with exo-AAV and exo-AAV-CD9GFP of serotypes 1 and 6 and the per-
centage of GFP positive cells was evaluated by flow cytometry analysis one week
after transduction.
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3.3 Lentiviruses as neuronal delivery tool
As a short chapter in this study but for completion of the delivery tool platform, we gen-
erated replication deficient HIV-1-based lentiviruses. Analogous to the rAAVs and VLPs
in this study (see 3.1 and 3.4.2), three di erent viruses were produced, transferring one
of the commonly used promotors for neuronal delivery (CAG, CaMKII, and hSyn) and
the fluorescent transgene GFP.
As recently published in a paper where I am contributing author, we first discovered
the enhancing e ect of CD9 on the secretion of exosomes and the infectivity of vectors
during the production of lentiviruses (see supplemental 5.5 and Böker et al. (2017)). In
combination with the rAAVs and exo-AAVs the here produced lentiviruses are a suitable
tool for future investigations to clarify the mode of action of CD9 which still hasn´t been
unraveled yet.
We tested the three lentiviral preparations for their functionality. Therefore, we applied
equal volumes of lentiviral samples on HeLa cells and took micrographs 72 h post trans-
duction (Figure 25). The lentivirus with CAG and CaMKII promotor drove a strong GFP
expression in a high number of cells, whereas hSyn only drove expression in a low number
of cells.
The functionality of the lentiviruses was qualitatively proven. This allows comparing the
tools´ e ciency in upcoming approaches in combination with exo-AAVs and VLPs with
or without retargeting in transduction of the target tissue.
Due to their faster and stronger expression, the lentiviruses can be used to investigate
new opsin constructs in ex vivo experiments which require a quick expression onset.
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Figure 25: Lentiviruses deliver the transgene in HeLa cells Lentiviral constructs driving
GFP expression under CAG, CaMKII and hSyn promotors were tested for func-
tionality in HeLa cells.
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3.4 Virus-like particles as delivery tool for neuronal targets
In our group, the non-viral JC Polyoma virus-derived VLPs have mainly been used to
deliver small RNAs in vitro and in vivo so far. The aim of this chapter was to develop
DNA delivery strategies with enhanced safety which can potentially be applied to gene
therapy and particularly to optogenetics. Moreover, we aimed a neurotrophic retargeting
of the VLPs´ tropism.
3.4.1 Delivery of linear expression cassettes and MIDGE vectors
Aiming to gain a space-saving and secure gene construct, the pGEM-T Easy CAG-GFP-
WPRE was generated. A linear expression construct of around 2.5 kb in size can be
generated by enzymatic digestion with SphI and SacI. This was constructed analog to the
control rAAVs and lentiviruses to allow an easy comparison of the three delivery tools
(see 3.1 and 3.3). The linear construct lacking the bacterial plasmid backbone has the
benefit of a reduced number of CpG-motifs, which are prone to cause an immune response
(Krieg, 1999).
More importantly, to make the delivery of linear DNA with the VLPs even safer, the
restriction sites were selected in a way to enable the generation of MIDGE vectors
(Schakowski et al., 2001). The linear DNA was purified and oligonucleotides, forming
a hairpin structure, were used to recircularize the DNA. Subsequently, all remaining
oligonucleotides and non-circularized DNA were digested by the T7 exonuclease (Figure
26 A). As control for a complete digestion, linear DNA was incubated at the same condi-
tions and aliquots of the samples were analysed on agarose gels (Figure 26 B). We found
that the MIDGE vector was resistant to T7 exonuclease digestion, whereas the linear
DNA was completely digested. Furthermore, we could prove that no oligomerization had
occurred, which would multiply the construct size.
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Figure 26: Production of MIDGE vectors (A) The MIDGE vector derived from an en-
zymatic digested plasmid. Its cohesive ends were connected with oligonucleotides.
Remaining not-closed DNA was digested by a T7 exonuclease. (B) Agarose gel to
prove successful T7 exonuclease digestion.
As a proof-of-concept, equal amounts of MIDGE vectors and the linear expression con-
struct, packaged in VLPs, were applied on SKBR3 cells and the percentage of GFP
positive cells was evaluated 48 h after transduction via flow cytometry analysis (Figure
27).
In repeated experiments we found that both constructs transduced the cells in the same
range.
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Figure 27: SKBR3 cells express linear and MIDGE vector after VLP delivery
MIDGE vectors and linear DNA were packaged in VLPs and applied on SKBR3
cells. The red line in the dot plots indicates the Log(GFP) value of two standardde-
viations over the median fluorescence intensity of non-transduced cells. Cells above
this value were considered as GFP positive. Whereat the percentage of cells above
the cuto -value from wild type cells was substracted.
3.4.2 Virus-like particles for neuro-optogenetics
For the use of the VLPs in neuro-optogenetics we evaluated whether linear expression
cassettes with the CaMKII, and the hSyn promotor can be used to address a neuronal
expression. We obtained expression of the transgene in HeLa cells with both promotors
when transduced with rAAVs and lentiviruses (see 3.1 and 3.3). Therefore we then trans-
duced HeLa cells with VLPs, harboring equal amounts of linear expression cassettes with
the CAG, the CaMKII and the hSyn promotor and observed them for reporter gene ex-
pression.
But only cells transduced with the CAG promotor construct expressed GFP (data not
shown).
As the transduction of HeLa cells with the CaMKII and the hSyn promotor lead to no
expression, we evaluated their ability to drive expression in dissociated cortical cultures
of the Wistar rat in the next step.
We found none of the constructs leading to a GFP expression visible in fluorescence mi-
croscopy. Moreover, cortical cultures transduced with cargo loaded or even empty VLPs
died. The application of the reassembly bu er alone (in which the VLPs are suited after
loading) did not a ect the cell survival. And rebu ering of the VLP samples with the
cell culture medium and pre-equilibration also caused cell death after transduction. A
decrease of the VLP amount slowed down the cell death, but again, no GFP positive cells
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were detected (data not shown).
We concluded that our expression cassettes with neuron-specific promotors are not suit-
able to lead to a transgene expression in Hela cells when used as cargo for VLPs. Fur-
thermore, cortical cultures of the Wistar rat react highly sensitive with cell death to the
application of VLPs.
Neurotrophic retargeting of virus-like particles
We produced the VP1 protein which forms the self-organised VLP capsids in insect cell
cultures and loaded the capsids with its cargo in vitro under ambient bu er conditions.
The broad tropism of the JC polyoma virus-derived VLPs to 5-HT2 receptor positive cells
can be modified and adjusted on the course of biochemical manufacturing. Therefore, we
express retargeting molecules, e.g. single chain variable fragments in E. coli or P. pastoris
and chemically crosslink them via a maleimide-linker on the VLPs surface (Figure 28).
Having one binding domain with each VP1 for the maleimide and the capsid consisting
of 72 pentamers, one capsid has 360 potential binding-sites. Additionally, the VLPs´
surface has a high a nity for carbohydrates, e.g., the naturally occurring LSTC. We
found that biotin-coupled LSTC is as well suitable to attach retargeting molecules to the
VLPs surface when they, in turn, are expressed as streptavidin fusion protein.
Notably, the retargeting molecules can also be utilised to alter the tropism of exo-AAVs
and lentiviruses when expressed and be located in the membrane of the producer cells.
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Figure 28: Production and retargeting of VLPs The VP1 protein is recombinantly ex-
pressed in insect cells. The purified VP1 protein reassembles to capsids in abun-
dance of DNA and CaCl2, incorporating the cargo DNA. Retargeting molecules can
be expressied in E. coli or P. pastoris and be attached to the VLPs surface. The
native and the retargeted VLPs can be directly applied on cells.
After we had demonstrated that we could direct the delivery of the linear expression
cassette to human cancer cells by switching the VLPs´ tropism towards the Her2/neu, a
growth hormone receptor frequently overexpressed particularly on breast and colon cancer
cells (Experiments and Figure 29 were kindly provided by Stefan Schneider, German
Primate Center, Göttingen), we aimed for a retargeting to neuronal cells.
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Figure 29: VLP retargeting to Her2/neu positive cells Flow cytometry analysis of HeLa
and SW40 colon rectal cancer cell lines transduced with the CAG-GFP expression
cassette. Native VLPs transduced 25 % of both cell lines. Her2/neu scFv retargeted
VLPs did not transduce HeLa cells anymore but 50 % of SW480 cells. This figure
was kindly provided by Stefan Schneider (German Primate Center, Göttingen).
We decided on a scFv that binds the receptor tyrosine kinase (TrkB) which is a neu-
rotrophic factor receptor expressed in the central and peripheral nervous system and other
tissues (Gupta et al., 2013). Due to its humanized glycosylation patterns, we preferred
to express scFvs in the humanized P. pastoris. The expression constructs pPICZ–A-
TrkBscFv and pPICZ–A-TrkBscFv-Streptavidin were designed with an N-terminal cys-
teine for crosslinking and a C-terminal 6xHis-tag for FPLC purification and Western Blot
detection. The plasmids were transformed into P. pastoris, and selection marker resistant
clones were analysed for expression. Based on western blot detection, we found that none
of the screened clones expressed the retargeting molecules.
Due to this result, the expression system was changed to E.coli (SoluBL21® and BL21
Star®(DE3)) and the pET28a(+) expression vector system. Various incubation tempera-
tures (room temperature and 37°C), incubation times and IPTG concentrations (0.1 mM
up to 1 mM) for expression induction were tested.
The bacteria were harvested, lysed and the protein abundance in the soluble and non-
soluble fractions was detected via western blot. The two retargeting proteins (TrkBscFv
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32 kDa and TrkBscFv-Streptavidin 45 kDa) were well expressed under high IPTG con-
dition, but stayed unsoluble under all tested conditions. Furthermore, several bands of
higher and lower weight were visible for the TrkBscFv-Streptavidin construct.
As proteins for FPLC purification need to be soluble we could not pursue the retargeting
approach with the TrkBscFv.
TrkBscFv TrkBscFv-Streptavidin
M star                         solu
70
kDa
55
35
40
M star               solukDa
70
55
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40
25
Figure 30: TrkBscFvs were expressed in E. coli but were only found in the unsolu-
ble fraction Coomassie blue stained SDS-PAGEs and western blots of the whole
cell lysate from SoluBL21® (solu) and BL21 Star® (star) expressing the 31 kDa
TrkBscFv and 45 kDa TrkBscFv-Streptavidin.
In 2016, Javed et al. published the use of an N-terminal truncated version of the ra-
bies virus glycoprotein (RVG), which binds to the n-Acetylcholine receptor (nAchR), and
thereby delivered a cargo siRNA to the CNS.
We added a C-terminal Gly-Ser-Gly-Ser-Cys sequence to the six nucleotides truncated
version (RVGN6) to enable its chemical crosslinking on the VLPs.
For the retargeting, we loaded the VLPs with the linear expression cassette (see 3.4.1), at-
tached the maleimide-crosslinker and incubated them together with the reduced RVGN6
in 30 X excess. As controls, we used the loaded, but native VLPs to determine the per-
centage of transduction with the native tropism to the 5-HT2 receptor. Only the peptide
incubated with the DNA was used as negative control and to disprove that the peptide
itself enabled delivery of the DNA. We only attached the crosslinker to the capsid which
should completely mask the tropism of the VLPs. The native VLPs without crosslinker
but only the peptide were used to elucidate whether the unbound RVGN6 would promote
the transduction of nAchR positive cells.
We transduced three cell lines (SKBR3 and 3T3 are nAchR negative, SH-SY5Y is nAchR
positive) with the five samples and evaluated the percentage of GFP positive cells five
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days after transduction. Due to the lack of a cell line, that is not transduced by the native
VLPs but expresses nAchR, we used the neuroblastoma derived SH-SY5Y cell line. This
should be transduced by both, the native VLPs and also by successfully retargeted ones.
The murine fibroblast cell line 3T3 lacks the nAchR and should not be transduced after
a successful retargeting (Lentz, 1990; Javed et al., 2016; Kovalevich and Langford, 2013).
The native VLPs and VLPs incubated with the peptide alone transduced all three cell
lines with at least 30 % GFP positive cells up to over 70 % for SH-SY5Y cells. No cells
were transduced with our negative control. More interestingly though, both, the VLPs
with attached crosslinker alone and the VLPs incubated with crosslinker and RVGN6
transduced less than 10 % of the three cell lines.
To sum up, we assume that the crosslinker was attached to the capsid because the native
VLPs transduced all cell lines but their transduction e ciency was highly reduced after
the incubation with the crosslinker. Therefore we conclude that the reduced transduction
e ciency of crosslinker and RVGN6 incubated VLPs can either be caused by a missing
attachment of the retargeting peptide or the attached peptide prevents the binding to the
cells.
Alltogether, VLPs are a powerful and easy to handle delivery tool. Furthermore, in
combination with the MIDGE vector strategy and its possible alteration of tropism, they
are also a promising tool for gene therapy. However, its ex vivo application and retargeting
to nervous tissue requires further development.
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Figure 31: RVGN6 retargeting of VLPs (A) Transduction e cency of RVGN6 retargeted
VLPs and controls was determined via flow cytometry analysis as percentage of
transduced cells on day 5 after transduction. (B) Micrographs of SKBR3, SH-
SY5Y and 3T3 cells transduced with native VLPs as positive control and RVGN6
and the DNA alone as negative control.
116
4 Discussion
Gene therapy projects mainly focus on the target identification or the constructs for
specific research and therapy purposes. Others focus on engineering the delivery tools
which are suitable for several applications. This thesis contributes to the latter. The
main goals are to engineer viral and non-viral delivery tools for the gene transfer to
nervous tissue. And an enhanced production of exo-AAVs and a neurotropic retargeting
of VLPs. By that, we provide a toolbox to enhance the safety and e ciency of gene
therapy.
A recently approved gene therapy for macula degeneration has been launched into the
market with costs of approximately 450,000 US dollar per eye. Glybera in Europe even
had to be taken from the market due to unachievable prices which made it unprofitable
for the company to pursue its commercialisation.
The optimization of the tools and its production is a crucial element to reduce the costs
of gene therapy. I hope that my work will help to make gene therapy achievable for a
broader audience that would not be able to a ord the high costs but then would benefit
from current and future therapies.
4.1 Standard rAAV production and evaluation
4.1.1 Standard rAAV production and evaluation on human cell lines
With the rationale to engineer the exo-AAV production and purify rAAVs to in vivo grade
for the use in non-human primates we implemented the standard rAAV production.
We successfully set up the production of five serotypes (1, 1/2, 2, 5, and 6) which enables
investigators to choose the best-suited serotype for their future projects. Reports on the
transgene delivery to neurons in the non-human primate brain utilise rAAV5 (Taymans
et al., 2007; Gerits et al., 2012; Diester et al., 2011). In a cooperation project with such
a group, we decided to implement the purification based on the serotype 5. Of the 12
known serotypes, AAV5 is the most divergent one and is described to be complicated
to purify and ine cient to apply in vitro (Janovitz et al., 2014). We concluded that a
successful purification and ex vivo test systems should enable a high standard production
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of the other serotypes and their pre-animal test as well.
During their production, rAAVs are found in the cells and the medium. According to
Vandenberghe et al. (2010), rAAV5 mainly remains in the cells and therefore our harvest-
ing protocol uses the crude cell lysate. However, to increase the yield of other serotypes
which are released from the cells, one should also harvest the rAAVs from the media.
This can be performed by, e.g., PEG-precipitation (Arden and Metzger, 2016), tangential
flow filtration (Clément and Grieger, 2016) or ultracentrifugation, as done for exo-AAV
harvest (see 3.2).
Centrifugation-cleared crude lysate as a screening tool -With the rationale to provide sev-
eral serotypes, we produced crude lysates of five commonly utilized serotypes and applied
equal volumes of workflow preparations on five human cell lines to evaluate their trans-
duction profile (Figure 6). The centrifugation-cleared crude lysate is the first applicable
rAAV sample with the least required hands-on time and minimal equipment compared
to more complex purification protocols. Within this study, the transduction e ciency
was compared by the % of GFP expressing cells, without the inclusion of the expression
level. We chose GFP as reporter gene because this fluorophor enables the identification
of expression by simple fluorescence microscopy and by flow cytometry, both on a sin-
gle cell level. Within neuro-optogenetics it is crucial to achieve a su cient expression of
the opsins in every single cell, essential to manipulate the cells electrical potential. In
contrast, luciferase which is used in several studies only allows the quantification of the
whole cell population protein expression (György et al., 2014). It is also more applicable
for research projects that later aim to express, e.g., secreted lysosomal enzymes to treat
storage diseases (Janson et al., 2002).
More interestingly, our data are in accordance with the study of Ellis et al., who published
the comparison of transduction e ciencies of several rAAV serotypes in 2013. Di erent
to our study, they applied equal numbers of viruses. Considering both studies, we can
conclude that our production gained the same number of viruses for all serotypes.
Our findings provide the ability to choose the best transducible cell line in case that a
serotype should be evaluated, or to select the right serotype for the desired cell line that
should be transduced. In general, rAAV2 with the constitutive CAG promotor was most
e cient on all cell lines. With the HeLa cell line being superior susceptible for almost all
serotypes and HEK cells for rAAV1, we subsequently used them for the quantification of
the functional titer (see 3.1.1 and 3.2.2).
Production of a good quality virus - The two good quality features of a viral sample are
their high functional titer and high purity. We therefore looked for a protocol, yielding a
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high titer and pure sample and compared our preparations with reference viruses which
are used in several publications (see 2.3.7) (Zhang et al., 2010; Gerits et al., 2012; Diester
et al., 2011). The output of the genomic titer can be the same for di erent purification
protocols, but the purification can influence the bioactivity of an apparently intact par-
ticle as, e.g., longer exposure to cesium chloride minimizes the bioreactivity (Hermens
et al., 1999). An interesting, but not yet applicable finding under GMP conditions is that
cellular contaminants can enhance the vectors‘ transduction e ciency (Tenenbaum et al.,
1999).
Centrifugation purification and concentration - As a fast and low equipment-requiring
protocol, we first elucidated the purification and enrichment e ect of a 21,000X g cen-
trifugation which other groups use for virus purification for in vivo experiments in ro-
dents (personal communication with Carola Gregor, Max-Planck-Institute for Biophysical
Chemistry, Göttingen).
However, we only detected a two-fold enrichment of the virus and a minor decrease of
non-viral proteins which in conclusion did not reach our expectations of a high titer and
high purity preparation.
Density gradient based purification - Next, we performed a density gradient centrifuga-
tion to more e ciently enrich the viruses and to separate them from cellular proteins.
We chose this gradient based on the direct comparison of cesium chloride- and iodixanol-
based purification by Strobel et al. (2015) who determined a higher purity of iodixanol
gradient preparations. Besides the depletion of co-purified cellular proteins, the iodixanol
gradient allows the depletion of empty AAV capsids. These by-products contain no viral
genome, but they increase the amount of applied immunological targets. As an induced
immune response can limit the transduction e ciency and prevent a repeated injection of
the same serotype, it is essential to gain a high percentage of filled capsids. Additionally,
the iodixanol density gradient is applicable for other serotypes and has the advantage over
a cesium chloride gradient that iodixanol is inert in animals (Larsen et al., 1995).
For a laboratory-internal identification of the fractions with a high virus content we de-
termined the genomic and functional titer of each gradient fraction. In the next step,
to identify pure fractions, which only contained the virus, single-fractions were dialysed,
concentrated and proteins were visualised on a silver-stained SDS-PAGE. Based on the
visual bands the purity of fractions 13-18 (which also contained a high amount of the
functional viruses) was confirmed, as impurities were visualised upon the upper fractions.
To remove the iodixanol and thereby decrease the viscosity of the sample and to concen-
trate the virus in following preparations, the fractions 13-18 were pooled, dialysed and
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concentrated, increasing the titer up to 1011 vg/ml.
rAAV column purification - As an alternative or additional purification method, we elu-
cidated FPLC based protocols with several columns. It is important to know that each
serotype requires a specific equipment and protocol. However, none of the performed
column and bu er combinations successfully bound the virus. Thus setting up FPLC
protocols requires a detectable amount of the vector we cannot exclude that the total
amount of applied virus was too low when comparing the applied viral load with a re-
cent publication (Nass et al., 2017). This reflects once again that the rAAV purification
requires a specialisation of the laboratory for rAAV production and even published pro-
tocols cannot right away be applied.
4.1.2 Quality control and comparison with a reference virus
Having set up a suitable purification protocol in our laboratory, we systematically com-
pared our rAAV-sample quality with commercial reference viruses. We now provide a
pipeline for rAAV production, purification and quality control which is further described
and summarized in Figure 32.
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Figure 32: Workflow of rAAV production, purification and quality control With a
plasmid from the rAAV genetic toolbox and a helper plasmid, determining the
serotype, one of 800 di erent rAAVs can be produced. Double transfection of plas-
mids in HEK-AAV cells leads to formation of rAAVs within the cell. rAAVs in the
crude cell lysate are purified from cell debris and empty capsids with an iodixanol
density gradient. Fractions with pure and genome-containing capsids are dialysed
and concentrated for a high titer preparation. Its quality is checked and deter-
mined by its purity (Electron microscopy (EM) and silver stain), high genomic
titer (qPCR) and functionality (flow cytometry titer and transduction in vitro and
ex vivo). 121
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Genomic and functional titer - Routinely, the genomic titer of a rAAV sample is declared,
and a high titer is in the range of 1012 to 1013 vg/ml. We set up a real-time PCR based
quantification of the genomic titer with a set of primers binding within the WPRE se-
quence. This protocol can be applied for most of the rAAV plasmids and also for the
quantification of the used expression construct for VLPs (see 3.1.2 and 3.4.1).
The quantification results can di er depending on the amplified sequence, as published
by Wang et al. (2013a). To circumvent this bias, we quantified three reference viruses
and found that our measurements were on average two-magnitudes lower as the declared
titer (1012 versus 1010 vg/ml). Besides the measurement bias, the storage and thawing
cycles can reduce the titer, even if rAAV5 is hugely stable at short-term incubation at
high temperature (Bennett et al., 2017). Compared with the reference, our self-produced
virus has consequently a one magnitude higher genomic titer.
Most important is the functional titer, i.e., the concentration of transducing units, because
it determines the transduction and therapy success. The reference virus approximately
contained one magnitude more transducing units. In contrast to the CAG promotor
driven GFP expression of our virus, the reference virus harbored the CBA promotor and
no WPRE sequence. The chicken beta-actin (CBA) promotor and its derivative CAG
are both constitutive promotors that drive a comparable long-term and robust transgene
expression (Gray et al., 2011; Powell et al., 2015). As we quantified the functional titer
by the number of GFP expressing cells, neglecting the amount of expressed protein, it
was a suitable virus to compare with.
Comparing the ratio of the genomic and transducing titer (vg/TU) enables the direct
comparison of two viral samples with di erent genomic titers. A lower ratio determines a
higher functionality. With the utilisation of the given titer, this ratio is lower for the self-
produced virus. Assuming a two magnitudes lower genomic titer of the reference virus,
this slightly inverses the result.
Summing up, we achieved the production of a high titer and functional virus in compari-
son to the reference virus.
Sample purity - As mentioned, the second good quality feature of a virus sample is its
purity. Meaning that it only contains the three viral capsid proteins and as little as pos-
sible empty capsids. Upon administration in vivo, the capsid load should be kept as low
as possible to avoid an immune response and the empty capsids represent a non-useful
by-product.
First, we separated the proteins of our virus sample on an SDS-PAGE and visualised
them in high resolution with a silver stain. The reference virus contained only the three
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expected capsid protein bands, whereas in one of our productions an additional band with
approximately 20 kDa was visible. The second sample even contained a higher amount
of co-purified proteins. This raises the question why the second virus contained more co-
purified proteins. It could be explained like this: firstly, the amount of applied crude lysate
on the iodixanol gradient was higher for the second virus and thereby the cellular proteins
might have smeared in the lower fraction. And secondly, due to the manual fraction-wise
harvest of iodixanol gradients from top to bottom, proteins might have smeared in the
lower fractions. To circumvent this issue, we consider to keep the volume of applied crude
lysate rather low and to change the harvest procedure to a syringe-supported bottom-to
top handling.
Electron microscopy with negative-stained rAAV samples o ers the possibility to visualize
the capsids and to assess the percentage of full particles (Zeltner et al., 2010). Our prepa-
ration protocol contains manual handling steps in the second range and thereby allows
no quantitive titer comparison. However, we determined the percentage of filled particles
and found approximately 40% for the reference virus as well as for the two own samples.
We thereby fulfilled the quality criteria of the number of filled capsids.
However, others report vector preparations with over 90 % filled capsids. Grieger et al.
(2016) achieved this high percentage by a subsequent ion exchange chromatography which
uses the subtle di erence in charge of filled and empty capsids. Even if our production
fulfills the reference criteria, it might be a future approach to decrease the number of
empty capsids and further increase the quality of our preparation.
Additionally to the viral capsids, we found donut-shaped particles of around 10 microns
in diameter in both of our preparations. To identify this co-purified protein, we analysed
the corresponding SDS-PAGE gel area by mass spectrometry and observed ferritin light
and heavy chain, keratin, and trypsin as main hits.
In agreement with the detection of the 20 kDa protein in the SDS-PAGE and observations
of Strobel et al. (2015), we identified the co-purified protein as ferritin, derived from the
producer cell line. This is supported by the hypothesis that AAVs interact with ferritin
during its life cycle. Trypsin and keratin are well-known bias in mass spectrometry. Prior
to mass spectrometry the samples are treated with trypsin to fragment the proteins and
keratins are arising during the sample processing from the experimenters (Link et al.,
1999). Additionally, trypsin and keratin did not fit in the molecular mass profile of the
excised gel area (20 kDa vs. approximately 60 kDa). Again, an adjustment during ion
exchange chromatography was shown to separate rAAVs from ferritin (Grieger et al.,
2016). The potential immunogenicity or toxicity of ferritin as an adjuvant in the in vivo
application of rAAVs remains elusive because literature lacks studies on this subject to
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our knowledge. The application of both of our viral batches in the mouse cochlea showed
none of those e ects (see 3.1.3).
Genetic toolbox for straightforward expression construct generation - To further simplify
the generation of a variety of rAAVs, we generated a genetic toolbox comprehending var-
ious promotors, opsins and reporter genes with optimised restriction sites. Thereby 80
combinations in straightforward and quick clonation steps are feasible and more impor-
tantly, also the easy inclusion of further genes. In addition to the rAAV production, this
simplifies the production of lentiviruses and expression cassettes for VLPs as well. We
provide a versatile, powerful tool that facilitates quick vector production for upcoming
research demands.
Functional opsin expression - As proof of principle and to complete the rAAV pipeline,
we confirmed that our virus drives a functional opsin expression allowing the generation
of an illumination evoked photocurrent. HeLa cells can be used for the whole pipeline up
to the voltage clamp recording.
To sum up, we implemented a pipeline for rAAV production and quality control with a ge-
netic toolbox that enables vector production (rAAVs, lentiviruses and VLPs) in a versatile
and experiment-demanding way (Summarized in Figure 32). We provide an expression
study of various serotypes, promotors, and cell line combinations which supports future
experiments with the choice of the best suitable cell line or serotype. We also provide
the information that rAAV5 can only limitedly be tested in vitro but when the gene of
interest is an opsin, its functionality can be confirmed in a voltage clamp setup.
In comparison to our reference viruses, we can claim to have a high titer and functional
virus production that was proven by ex vivo applications in the next step.
4.1.3 Application of rAAVs ex vivo and in vivo
Ex vivo application of rAAV serotypes to elucidate their potential for gene therapy
Human mesenchymal stem cells - Mesenchymal stem cells (MSCs) have attracted atten-
tion as a vehicle for gene therapy in regenerative medicine with their multi-potent ability
to di erentiate into various cell types, e.g., adipocytes and neurons (Mohammadian et al.,
2016).
Analogous to our experiment in which we gained the expression profile of our five rAAV
serotypes on immortalized human cell lines, we characterised them on MSCs derived from
the Warton´s jelly of the umbilical cord of three donors. Interesting to our knowledge was
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the diversity of susceptibility not only between the serotypes but also between the donors.
rAAV serotype 2 robustly performed on all three donor MSCs what might explain the
preferred usage of this serotype in recent studies (Stender et al., 2007). Nevertheless, the
serotype 6 and the chimeric 1/2 partially achieved a higher transduction rate. According
to our data presented here, we strongly suggest investigators to elucidate patient-wise
which serotype is superior.
As a follow-up to this study we planned to elucidate whether the gene manipulation pre-
di erentiation to neurons and osteoblasts keeps constant or is silenced.
Cortical cultures of the Wistar rat and three non-human primates - With the ethical
obligation to minimize the need of in vivo experiments and animals as tissue donors
for ex vivo experiments we tested our rAAVs on cortical cultures of the Wistar rat and
three non-human primates in the next step for the neuronal delivery. The tissue came
from animals which had been euthanised for other reasons and where the cortex was not
required for further examinations. This, especially for the non-human primates, limited
the excess to the material, especially from young individuals.
Acute cortex slices could be cultivated from all species, whereas dissociated cultures could
only be gained from the Wistar rat. As tissue from younger individuals has a more
extended viability in culture, we assume that the material from even newborn or adult
non-human primates is not suitable to lay out a culture. The expression profile of the
five serotypes with constitutive and neuron-specific promotors on dissociated cultures
pointed out that the serotype 5 mainly infects glia cells (based on morphological cell type
identification). It surprisingly also drives an expression with the CaMKII promotor that
is widely claimed as neuron-specific (Taymans et al., 2007). The rAAV2 was the only
serotype transducing no cells.
These results are in agreement with Howard et al. (2008) who also found no neuron-related
expression using another constitutive, the CMV promotor for rAAV5. They described a
late and rare onset of expression for the serotype 2, which might have been out of our
observation period.
Expression was only detected in few cases when an opsin was included besides the reporter
gene. Our study illustrates that, e.g., serotype 1 and the chimeric 1/2 are broadly e ective
ex vivo and can also be used in voltage clamp experiments. But we also reasoned that
rAAV5 with constructs for neuronal targeting needs to be applied in vivo or, e.g., on
cerebral organoid models of the brain (Lancaster et al., 2013).
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In vivo applications
Transduction of rAAV5 in the mouse cochlea - The cochlea is a well-established target
for rAAVs as for the aim to restore hearing with optogenetic implants (György et al.,
2017; Moser, 2015). In support of the above-discussed results this o ered us the oppor-
tunity to assess the in vivo potential of our viral batches. We injected the two high titer
viruses that were also addressed in the quality control section (see 4.3) in the cochlea of
mice and visualised the transduced cells in immunofluorescence stainings. Both viruses
transduced some supporting cells. No high number of transduced cells was expected thus
the serotype 5 is none of the preferred serotypes for cochlea transduction. For the CAG
promotor, it is published that it can drive a high expression in murine cochlea cells (Liu
et al., 2007). Based on the micrographs we did not identify any changes at the injection
sites and thereby conclude that the viral samples are safe for application.
Transduction of rAAV5 in the cortex of Macaca mulatta - In the course of an experiment
in our cooperation with the Cognitive Neuroscience Laboratory and the Neurobiology
Laboratory (Deutsches Primatenzentrum GmbH, Göttingen), which focused on the injec-
tion strategy and viral spread, a purchased and a self-produced virus were injected in the
dorsal and ventral pre-motor cortex of a Macaca mulatta. The animal was euthanised ten
weeks post-virus injection and the brain regions processed for immunofluorescence stain-
ings. Based on the detected transgene expression of the reference virus, we concluded that
the injection procedure was working. For the self-produced virus, no transgene expression
related to this virus was visualised in the adjacent neuropil but alterations regarding a
lower background fluorescence intensity and a reduction of NeuN positive cells. We can
thereby make no conclusions about the virus functionality in the cortex of Macaca mu-
latta.
The alterations of the neuropil can have various reasons: a mechanic injury caused by the
injection, neuropathogen virus infection, ischemia, anoxia or hypoglycemia (Vandevelde
et al., 2012). For a detailed investigation of the trigger, advanced histological stainings
could be performed to examine, e.g., the glia cells‘ reaction. Additionally, control in-
jections of the virus sample bu er alone and a control substance, like PBS, could be
revealing.
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4.2 CD9GFP over-expression increases the yield of exo-AAV1
Since their discovery in 2012 by Maguire and colleagues, exosome-associated AAVs (exo-
AAVs) have been a promising tool with several advantages over standard rAAVs. They
fullfill the requirements for a successful gene-therapy: they have an increased transduc-
tion e ciency and an increased resistance against anti-AAV antibodies in vitro and in
vivo. Additionally, as for lentiviruses, their lipid membrane can be modified to alter the
tropism. The pre-existence of anti-AAV antibodies in the human population and the
low transduction e ciency of several targets are major hurdles for gene therapy (Meliani
et al., 2017; Maguire et al., 2012).
Many reviews point out the need for improved protocols for a higher yield of rAAVs,
which also holds true for exo-AAVs (Meliani et al., 2017). Furthermore, more e cient
vectors are required to decrease the high rAAV doses of up to 1014 vector genomes per
kg of body weight to achieve a gene expression that is su cient for the treatment, e.g.,
in the CNS (György and Maguire, 2017). We examined (as proof of principle) with an
exciting outcome how a minor modification in the production protocol can increase the
release of exosomes and influence the yield and e ciency of exo-AAVs.
In the publication where I am a contributing author, we found that over-expression of
CD9, an exosomal marker-protein, led to an increased release of exosomes in several
human cell lines and more e cient lentiviruses (Böker et al., 2017).
Here, we demonstrate that the exogenous expression of CD9GFP in HEK-AAV cells in-
creases the transduction e ciency of exo-AAV1-CD9GFP for 26% ± 4.9% (mean±SD) in
comparison with exo-AAV1. We found that the increased transduction e ciency is likely
based on the higher yield of vesicle-bound rAAVs.
First of all, we generated HEK-AAV cells by lentiviral transduction that over-express a
GFP-fusion protein of the tetraspanin CD9. As previously performed, we isolated the ex-
tracellular vesicles using PEG precipitation and additionally with the ultracentrifugation
protocol, which is the standard protocol for exo-AAV harvest. We measured the vesicle
size and concentration by NTA. Assuming as reported that rAAV production does not
influence the vesicle release, we concluded that the same distribution would be found dur-
ing rAAV1 production, which we could not reassure due to safety precautions (Maguire
et al., 2012). However, to mimick rAAV production conditions we transfected the cells
with pAAV-CAG-GFP but without the helper plasmid.
As we published for additional cell lines, our NTA data show a decreased size profile of
the extracellular vesicles for the CD9GFP over-expressing cell line. And the exosome con-
centration in the PEG precipitation was increased as well as unproportionally high in the
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100 x g pellet. The comparison of both methods furthermore revealed that the increased
output of exosomes is no artifact of the PEG precipitation.
We then analysed the genomic titers of the exo-AAV harvesting steps (media, 20 k X g,
100 k X g, and supernatant) and found no significant di erences in vector production
between the wild type and CD9GFP over-expressing cells.
Using an iodixanol gradient analysis to distinguish between free and vesicle-bound rAAVs,
we found that the percentage of vesicle-bound rAAVs increased upon CD9GFP over-
expression. The distribution of free and exosome-bound vectors in the gradient was
comparable to other reports for exosomes, rAAVs, and other enveloped viruses, e.g. HIV
and Hepatitis C (Böker et al., 2017; György et al., 2014; Liu and Berkhout, 2014; Cantin
et al., 2008). The results prompted us to propose that the enhanced transduction e -
ciency of exo-AAV1-CD9GFP on HEK cells is the consequence of the increased number of
vesicle-bound AAVs.
A current study found that another non-enveloped virus, in that case hepatitis, occurs
as a membrane associated form comparable to naturally enveloped viruses (which have
additional viral glycoproteins in their envelope) and originates from the cellular exosomal
pathway (Nagashima et al., 2017). These findings indicate even more that the association
of rAAVs and exosomes is not artificially induced by the experimental protocol but found
for several viruses.
Similar to the over-expression of CD9GFP, the production of exosomes and the release of
viruses could be increased by the expression of the viral glycoprotein VSV-G or treatment
of hepatitis E producing cells with the lysosomal inhibitor bafilomycin A1. In contrast,
a knock-down of the exosome machinery reduced the release of viruses to the media
(Maguire et al., 2012; Nagashima et al., 2014; Alvarez-Erviti et al., 2011). These results
already demonstrate that positive modulation of the cellular exosome pathway can be
used to alter the amount of released, vesicle-associated viruses. For the first time we
demonstrated that this also happens for exo-AAV1 and we hypothesize that a combined
approach with additional administration of bafilomycin A1 might further increase the ex-
osome and exo-AAV1 production.
Future experiments should clarify the biophysical properties of the high-CD9 vesicles and
disclose whether the tetraspanin CD9 stabilizes the lipid membrane, enhances the interac-
tion with the rAAVs or mediates a more e cient fusion with the target cell. We therefore
provide a rAAV production and test pipeline, as well as rAAV and lentivirus plasmids
with the same genetic information (see 3.1 and 3.3) which can serve to unravel the mode
of action that is currently unknown.
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As we consider our experiments as a proof-of-principle, we used our established produc-
tion protocol for standard rAAVs. This uses the helper-free system of E1 transformed
HEK293 cells for virus production. Due to the potential loss of the transgene after many
passages, it requires work with low-passage cells. And thereby it prevented the complete
selection of CD9GFP-positive cells.
Therefore, we aim to generate a stable HEK cell line with concurrent, homogenous ex-
pression of CD9GFP and E1 with the purpose to further increase the exo-AAV yield and
minimize the required experimental handling.
4.2.1 exo-AAV serotypes 1 and 6 reveal a di erent expression profile on
mesenchymal stem cells than standard rAAVs
We then evaluated how the exo-AAVs of serotype 1 and 6 performed on MSCs and thereby
compared vectors produced in normal exosome-level and boosted exosome-level cells.
For the two donors and two serotypes we observed no clear di erence whether the exo-
AAV or exo-AAV-CD9GFP are more e cient. Whereas standard rAAV serotypes 1 and
6 performed similarly robust on donor #97 (see 3.1.3), both, exo-AAV1 and exo-AAV1-
CD9GFP performed drastically worse.
Recently, Meliani et al. (2017) hypothesized after competition experiments that exo-AAVs
enter the cells through a process that is independent of the serotype-specific AAV-binding
receptors. Hence, exo-AAV serotypes 1 and 6 should perform similarly. They addition-
ally showed that the nuclear translocation rate influences the expression level of rAAVs
(in their case exo-AAVs had been tra cked more e ciently than the standard rAAVs).
Therefore we might hypothesize that upon covering of the native tropism by encapsula-
tion in exosomes, rAAV6 has a more e cient tra cking to the nucleus and therefore a
higher transduction e ciency on the MSCs.
If the transduction is mediated by the exosomal envelope, we can conclude that the pro-
ducer cell line also influences the e ciency or the tropism of the exo-AAVs. Therefore,
the choice of another producer cell line might further increase the e ciency of exo-AAVs
on MSCs.
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4.3 Lentiviruses as neuronal delivery tool
Lentiviruses are the tool of choice when a high transduction rate with a fast and stable
protein expression is desired. This makes them a useful tool when new gene constructs,
e.g., for optogenetics, should be tested ex vivo and the desired vector, like a rAAV, is not
suitable (see 3.1.3). Our generated optogenetic toolbox (see 3.1.2) makes this even easier.
In addition to the test of new genes, new retargeting molecules for VLPs or exo-AAVs
can be tested with lentiviruses when expressed in the membrane of the producer cell line.
Furthermore, the generated lentiviruses are useful to investigate together with the exo-
AAV-CD9GFP the mode of action of CD9, with which it increases the infectivity of
lentiviruses and the yield of exo-AAVs (see Böker et al. (2017) and 3.2).
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4.4 Virus-like particles as delivery tool for neuronal targets
JC polyoma virus-derived VP1 VLPs (in short VLPs) are an exciting tool for research and
potentially application in clinics, which require a save and e cient delivery of the ther-
apeutic compound. Its advantages over viral delivery tools, like rAAVs and lentiviruses,
are that the recombinant VP1 protein is purified to homogeneity and loaded in an in
vitro disassembly/reassembly procedure (Goldmann et al., 1999). Thereby, the uncon-
trolled loading of cellular proteins, toxins or genetic material from the expression system
is avoided. The DNA- or RNA-cargos do not require viral sequences thus the encapsula-
tion is sequence independent (Moreland et al., 1991; Ou et al., 1999). Additionally, VLPs
induced no immune response in in vivo studies (Goldmann et al. (1999) and unpublished
data) and achieved a successful siRNA delivery for gene knock-down in an osteoporosis
rat model (Ho mann et al., 2016). With these findings, we considered its usability to
deliver genetic material into nervous tissue. This included utilisation of its native tropism
as well as aiming for a neuronal retargeting.
4.4.1 Safe DNA delivery by combination of VLPs and MIDGE vectors
As VLPs were mainly used for artificial RNA transfer in our group, we firstly constructed
a DNA expression cassette for easy visualization of transgene expression. Analogous to
the pAAVs and pLentiviruses (see 3.1 and 3.3) this plasmid uses a CAG-promotor to
drive GFP expression, and contains the WPRE sequence. Previous studies determined
approximately 3.5 kb as the payload limit for the VLPs. Because most plasmids exceed
this size (see appendix 5.1), two restriction sites within the plasmid enable an enzymatic
digestion to gain a linear expression cassette of 2.6 kb in length.
We also aimed to eliminate the CpG motif-rich bacterial plasmid backbone because it
bears the risk of immunological side e ects, as well as the open ends of linear DNA do
(Krieg, 1999). To adress the second threat, we generated so-called MIDGE vectors to
generate a monomolecular, linear DNA (Schakowski et al., 2001).
Our results showed comparable transduction rates of SKBR3 cells for the linear and the
re-circularized construct (see 3.4.1).
Since we identified the production of these MIDGE vectors to be very time- and cost-
intensive, we claim this approach as proof-of-principle. We intend to utilise MIDGE
vectors in upcoming in vivo studies with VLPs. Additionally, the use of the dual- or
the recently published triple AAV-strategy might bear a potential to transfer expression
cassettes for bigger proteins (McClements and MacLaren, 2017; Maddalena et al., 2017).
Such an approach would eliminate the size limitations of VLPs and broaden their usage
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for gene therapy approaches where larger transgenes are required.
4.4.2 Neuronal expression and retargeting of VLPs
For the neuronal delivery and transgene expression we followed two approaches:
• the restriction of expression by a neuronal promotor, enabling a broad delivery
• retargeting of VLPs, which would allow the targeted delivery of a strong expression
promotor
Similar to the rAAVs and lentiviruses which we tested for the activity of the CaMKII
and the hSyn promotors in HeLa cells (see 3.1), we used linear DNA derived from the
pAAVs and delivered them via VLPs. We previously observed that VLPs well transduce
HeLa cells and lead to a GFP-expression driven by the CAG promotor (see 3.4.2). But
none of both constructs with the neuron specific promotors led to a transgene expression.
We conclude that the lack of expression was due to the combination of the rather weak
promotors and the delivery via VLPs.
To exclude cell line artifacts, we tested the VLPs, similar to the rAAVs (see 3.1.3), on
primary cortical cultures of the Wistar rat. No GFP-expression was detectable and the
culture viability decreased dramatically in a dose-dependent manner. Pre-equilibration
and re-bu ering of the VLP sample pre-application could not circumvent this e ect.
Thus we could transduce primary rat osteoblasts and the neuroblastoma cell line SH-
SY5Y with VLPs and detect expression of the CAG-GFP construct, it could be explained
by the high sensitivity of neuronal cultures. Supported by the previous observation that
a culture of Callithrix jacchus glia cells was susceptible for VLPs delivering a flourescence
dye (Cy3) coupled small RNA.
We conclude that the ability of neuronal targeting with VLPs has to be elucidated in
another ex vivo model which is more robust. Possibly a denser cell structure, like in
cerebral organoid models of the human brain, supports the cell viability after the trans-
duction with VLPs (Lancaster et al., 2013). VLPs were found to work e ciently in vivo
without harming the individuum (Ho mann et al., 2016). An in vivo study using MIDGE
vector-loaded VLPs with both, constitutive and neuron-specific promotors and subsequent
analysis of organs and cell types for the reporter gene expression would help to unravel
the transduction profile of VLPs.
Another option to achieve a cell type restricted protein expression is, as previously de-
scribed, the use of promotors being inactive in o -target tissues (White et al., 2009). The
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option which we provide for the targeting of Her2/neu-receptor positive cell lines (can-
cer cell lines) is the modification of the VLPs‘ tropism via the attachment of retargeting
molecules. Having developed a functional retargeting molecule, this can also be used to al-
ter the tropism of exo-AAVs and lentiviruses. For these two membrane-enveloped viruses,
the retargeting molecule would be recombinantly expressed as a membrane-anchored pro-
tein in the virus producer cell line. When the virus is released from the cell, it will gain
the membraneuos envelope with the exposed retargeting molecule. Taken together, one
could compare the three tools and identify the best suitable one for a specific application.
The humanized strain of the yeast P. pastoris stands out due to its humanized glycosyla-
tion profile of recombinant expressed proteins in a sense that only a 5 times branching of
mannose is seen (Hamilton and Gerngross, 2007). Thereby it is our preferred expression
system for retargeting molecule expression, which we used to express the Her2/neu single
chain variable fragments (scFv) that altered the VLPs‘ tropism towards human cancer
cells (see 3.4.2). We constructed the expression plasmid for a scFv that should bind to
the tropomyosin receptor kinase B (TrkB), the receptor for BDNF which is expressed in
the central and peripheral nervous system and other tissues (Gupta et al., 2013). Un-
fortunately, no recombinant protein expressing P. pastoris clone could be identified in
repeated attempts.
Hence, we switched the expression constructs to the pET28- E.coli expression system and
achieved the expression of the retargeting molecules. However, the retargeting molecules
were unsoluble. The protein transcription rate and the folding of proteins expressed in
E.coli can be influenced by several cultivation parameters. In our case, we gained unsol-
uble proteins even when reducing the transcription rate by lowering the concentration of
the induction reagent IPTG or by decreasing the temperature and thereby increasing the
possibility of proper folding of a soluble protein (Schein and Noteborn, 1988).
Alternative approaches to gain a soluble protein would be the use of bacteria strains which
secrete the protein to the periplasm or the medium, or the co-expression of chaperons to
gain an improved protein folding (Mergulhao et al., 2005; De Marco, 2009). Additionally,
one could try to express the protein in insect cells as we do for the VP1 protein or in
human cell lines. These alternative approaches were not undertaken due to the restricted
time in the course of this study.
As a promising alternative, we tested a synthetic peptide derived from the rabies virus
glycoprotein (RVG) that was shown to specifically deliver siRNAs through the blood-brain
barrier (Javed et al., 2016). RVG binds to the n-acetylcholine receptor which is expressed,
e.g., in the neuroblastoma cell line SH-SY5Y but not in fibroblasts (Lentz, 1990; Javed
et al., 2016; Kovalevich and Langford, 2013). In our experiments, the native VLP trans-
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duced both cell lines and SKBR3 cells were used as our positive control for functional
VLPs. VLPs with the attached crosslinker alone, as well as with the crosslinker and the
retargeting molecule showed drastically reduced transduction of all cell lines. Based on
this result we can make no conclusion whether the crosslinking of the retargeting molecule
did not work or the molecule was crosslinked but did not bind to the cells.
Further experiments with an altered crosslinking protocol to enhance the crosslinking-
success will be elucidated. Because we utilised a rather short crosslinker, steric hindrance
might have not allowed the small RVG-proteins (scFvs are several folds larger) to bind
to the cell receptors when attached on the VLPs‘ surface. The use of a longer crosslinker
than the used one of 32.5 angstroms, might be successful.
In summary, we demonstrated that VLPs are a very useful, non-viral tool to deliver
DNA expression cassettes in vitro. We combined this technology with MIDGE vectors,
which will increase the safety of DNA delivery in in vivo applications. Even if we could
not achieve neuronal retargeted VLPs, our results contribute to the previous finding of
specific delivery of therapeutic expression cassettes via Her2/neuscFv-retargeted VLPs
into cancers cells.
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4.5 Conclusion and future directives
Gene therapy is a rising field in which the engineering of the delivery tools holds a big
promise to improve its e ciency and safety.
In this context, we worked on three delivery tools: the viral rAAVs and lentiviruses which
are well-established in gene-therapy, and the non-viral JC polyoma virus-derived VLPs
which are a promising tool. Our focus was on the rather new technology of exo-AAVs
which outperform standard AAVs regarding the transduction e ciency and the antibody
evasion.
Within this study, we provide a platform for a straightforward generation of expression
constructs with our genetic toolbox and the initiation of retargeting strategies which are
applicable for most of the tools. As the target, we chose nervous tissue with the exemplary
application of optogenetics, as we work in a cooperation that addresses neuro-optogenetics
in the non-human primate.
Several 
serotypes
rAAV
exo-AAV
Lentivirus
VLP
CD9GFP
Retargeting 
strategy
Genetic 
toolbox
Figure 33: Crosslink of engineering strategies Details described in the text.
Firstly we set up a pipeline for in vivo grade standard rAAV5 purification with in vitro
quality control and ex vivo tests which can be applied to further serotypes and exo-AAVs
as well. Each rAAV serotype exhibits a di erent tropism and expression pattern. We pro-
vide expression data for several serotypes with a constitutive and neuronal promotors on
human cells lines as well as on primary cells and tissue of human, rodent and non-human
primate origin.
One challenge for commercial gene therapy is the production of the delivery tools in a
high yield. For the first time we show that exo-AAVs produced in an exosome-enriched
environment have an approximately 26 % increased e ciency. To achieve this, we ap-
plied our previous finding that the over-expression of the exosomal marker-protein CD9
increases the exosome production in human cell lines. Moreover, our data indicate that
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the higher e ciency is due to an increased number of exosome bound viruses while the
overall secretion of rAAVs in the media stayed constant. By that, we provide a simple
and economical protocol to produce around 25 % more exo-AAVs with a minor additional
e ort.
Furthermore, we worked on a biochemical retargeting approach of VLPs towards neurons
by the attachment of retargeting molecules for two neuronal receptors. This approach
could be applied for exo-AAVs and lentiviruses as well. However, the successful retar-
geting has to be proven in the future. By combining the VLP-technology and MIDGE
vectors, we point out a safe way to deliver linear expression constructs which are less
potent to cause an immune response.
Together, these developments provide a handy way to improve delivery vectors which can
be tested and compared in the set up pipeline which will allow choosing the most e cient
one for future applications.
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5.1 Plasmid maps
5.1.1 rAAV genetic toolbox
pAAV-CaMKII-GFP
6092 nt
pAAV-hSyn-GFP
5289 nt
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v"
v"pAAV-CaMKII-eArch3.0-NdeI-eYFP
6986 nt
pAAV-CaMKII-ArchT-NdeI-
GFP
6570 nt
pAAV-Ef1a-GFP
6055 nt
156
5 Appendix
v"pAAV-CaMKII-eNpHR3.0-NdeI-eYFP
7075 nt
v"pAAV-CaMKII-eNpHR3.0-GFP
6982 nt
v"pAAV-hSyn-hChR2(H134R)-mCherry
6227 nt
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v"pAAV-CaMKII-Jaws-GFP7025 nt
v"pAAV-CaMKII-hChR2(H134R)-mCherry
7031 nt
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5.1.2 Linear expression cassette plasmids
pGEM-T easy-CAG-GFP-
WPRE
5466 nt
pGEM-T easy-CAG-GFP-
(WPREout)
4878 nt
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5.1.3 scFv expression plasmids
pET28aTrkBscFv
6185 nt
pET28aTrkBscFv-
Streptavidin
6566 nt
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5.2 Mass spectrometry analysis of impurity lanes
Table 45: Mass spectrometry hits
Number Identified proteins Molecular
weight
Total of
spectra
1 Ferritin light chain (Homo sapiens) 20 kDa 0.44 %
2 Trypsin (Sus scrofa) 24 kDa 0.37 %
3 Ferritin heavy chain (Homo sapiens) 21 kDa 0.33 %
4 Keratin type II cytoskeletal 1 (Homo sapiens) 66 kDa 0.19 %
5 Keratin type II cytoskeletal 2 epidermal (Homo sapiens) 65 kDa 0.13 %
6 Keratin type I cytoskeletal 10 (Homo sapiens) 59 kDa 0.12 %
7 Keratin type I cytoskeletal 9 (Homo sapiens) 62 kDa 0.089 %
8 Proteasome subunit beta type-5 (Homo sapiens) 28 kDa 0.089 %
9 Ferritin light chain (Bos taurus) 20 kDa 0.059 %
10 Tubulin beta-4 chain (Xenopus laevis) 50 kDa 0.049 %
11 Elongation factor Tu 1 (Escherichia coli) 43 kDa 0.05 %
12 Proteasome subunit alpha type-1 (Homo sapiens) 30 kDa 0.04 %
13 ADP-ribosylation factor 5 (Homo sapiens) 21 kDa 0.04 %
14 Proteasome subunit alpha type-5 (Bos taurus) 26 kDa 0.04%
15 Keratin, type I cytoskeletal 14 (Homo sapiens) 52 kDa 0.03 %
16 Proteasome subunit beta type-7 (Homo sapiens) 30 kDa 0.03 %
17 Tubulin alpha-1B chain (Bos taurus) 50 kDa 0.03 %
18 Actin-1 (Aedes aegypti) 42 kDa 0.03 %
19 40S ribosomal protein S18 (Bos taurus) 18 kDa 0.03 %
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20 Elongation factor 1-alpha, somatic form (Xenopus lae-
vis)
50 kDa 0.03 %
21 SUMO-activating enzyme subunit 1 (Homo sapiens) 38 kDa 0.03 %
22 Histone H2B type 1-B (Homo sapiens) 14 kDa 0.03 %
23 E1B protein, small T-antigen (Human adenovirus C
serotype 2)
21 kDa 0.03 %
24 ADP-ribosylation factor 4 (Homo sapiens) 21 kDa 0.03 %
25 Ferritin heavy chain (Equus caballus) 21 kDa 0.03 %
26 Proteasome subunit alpha type-7 (Bos taurus) 28 kDa 0.02 %
27 60S acidic ribosomal protein P2 (Bos taurus) 12 kDa 0.02 %
28 Destrin (Bos taurus) 19 kDa 0.02 %
29 60S ribosomal protein L12 (Bos taurus) 18 kDa 0.02 %
30 Proteasome subunit beta type-1 (Homo sapiens) 26 kDa 0.02 %
31 Green fluorescent protein (Aequorea victoria) 27 kDa 0.02 %
32 Heat shock protein HSP 90-beta (Equus caballus) 83 kDa 0.02 %
33 40S ribosomal protein (Bos taurus) 18 kDa 0.02 %
34 Glutamine synthetase (Homo sapiens) 42 kDa 0.02 %
35 60S ribosomal protein L26 (Bos taurus) 17 kDa 0.02 %
36 Ferritin heavy chain (Bos taurus) 21 kDa 0.02 %
37 Protein GlcG (Escherichia coli) 14 kDa 0.02 %
38 Eukaryotic translation initiation factor 5A-1 (Bos tau-
rus)
17 kDa 0.02 %
39 Maltose-binding periplasmic protein (Escherichia coli) 43 kDa 0.02 %
40 Serum albumin (Bos taurus) 69 kDa 0.02 %
41 DNA-directed RNA polymerases I, II, and III subunit
RPABC3 (Homo sapiens)
17 kDa 0.02 %
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42 Keratin, type II cytoskeletal 6A (Homo sapiens) 60 kDa 0.02 %
43 Eukaryotic translation elongation factor 1 epsilon-1
(Homo sapiens)
20 kDa 0.02 %
44 Hornerin (Homo sapiens) 282 kDa 0.02 %
45 ADP-ribosylation factor-like protein 2 (Homo sapiens) 21 kDa 0.02 %
46 Peptidyl-prolyl cis-trans isomerase A (Chlorocebus
aethiops)
18 kDa 0.02 %
47 Small nuclear ribonucleoprotein-associated protein B’
(Bos taurus)
25 kDa 0.02 %
48 ADP-ribosylation factor 3 (Drosophila melanogaster) 20 kDa 0.02 %
49 Proteasome subunit alpha type-4 (Bos taurus) 29 kDa 0.02 %
50 Transcription elongation factor B polypeptide 2 (Homo
sapiens)
13 kDa 0.02 %
51 Cellular nucleic acid-binding protein (Bos taurus) 19 kDa 0.01 %
52 Proteasome subunit alpha type-6 (Bos taurus) 27 kDa 0.01 %
53 Proteasome subunit beta type-6 (Homo sapiens) 25 kDa 0.01 %
54 40S ribosomal protein S14a (Anopheles gambiae) 16 kDa 0.01 %
55 60S ribosomal protein L11 (Bos taurus) 20 kDa 0.01 %
56 Proteasome subunit beta type-3 (Bos taurus) 23 kDa 0.01 %
57 N-alpha-acetyltransferase 50 (Bos taurus) 19 kDa 0.01 %
58 26S protease regulatory subunit 8 (Bos taurus) 46 kDa 0.01 %
59 40S ribosomal protein S20 (Bos taurus) 13 kDa 0.01 %
60 Cysteine and glycine-rich protein 2 (Bos taurus) 21 kDa 0.01 %
61 Nucleoside diphosphate kinase A 1 (Bos taurus) 17 kDa 0.01 %
62 Eukaryotic initiation factor 4A-I (Bos taurus) 46 kDa 0.01 %
63 ADP-ribosylation factor 1 (Bos taurus) 21 kDa 0.01 %
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64 High-molecular weight cobalt-containing nitrile hy-
dratase subunit beta (Rhodococcus rhodochrous)
26 kDa 0.01 %
65 Coatomer subunit zeta-1 (Bos taurus) 20 kDa 0.01 %
66 60S ribosomal protein L27 (Bos taurus) 16 kDa 0.01 %
67 Keratin, type II cytoskeletal 5 (Homo sapiens) 62 kDa 0.01 %
68 40S ribosomal protein S25 (Bos taurus) 14 kDa 0.01 %
69 Lysozyme C (Gallus gallus) 16 kDa 0.01 %
70 Ubiquitin-like protein 4A (Callithrix jacchus) 18 kDa 0.01 %
71 DNA-binding protein (Human adenovirus C serotype 2) 59 kDa 0.01 %
72 Ras-related protein Rap-1A (Bos taurus) 21 kDa 0.01 %
73 Small nuclear ribonucleoprotein Sm D2 (Bos taurus) 14 kDa 0.01 %
74 Sorting nexin-3 (Bos taurus) 19 kDa 0.01 %
75 Cyclin-dependent kinase inhibitor 2A (Homo sapiens) 17 kDa 0.01 %
76 Myosin light polypeptide 6 (Bos taurus) 17 kDa 0.01 %
77 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1
(Bos taurus)
18 kDa 0.01 %
78 Keratin, type II cytoskeletal 5 (Bos taurus) 63 kDa 0.01 %
79 High-molecular weight cobalt-containing nitrile hy-
dratase subunit alpha (Rhodococcus rhodochrous)
23 kDa 0.01 %
80 Ferritin heavy chain (Trichosurus vulpecula) 21 kDa 0.01 %
81 S-phase kinase-associated protein 1 (Bos taurus) 19 kDa 0.01 %
82 Small nuclear ribonucleoprotein Sm D3 (Homo sapiens) 14 kDa 0.00 %
83 Hemoglobin subunit beta-1 (Mus musculus) 16 kDa 0.00 %
84 Cofilin-1 (Bos taurus) 19 kDa 0.00 %
85 60S ribosomal protein L23a (Bos taurus9 18 kDa 0.00 %
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86 Proteasome subunit alpha type-3 (Bos taurus) 28 kDa 0.00 %
87 60S ribosomal protein L22 (Gallus gallus) 15 kDa 0.00 %
88 Adenine phosphoribosyltransferase (Homo sapiens) 20 kDa 0.00 %
89 GTP-binding nuclear protein Ran (Bos taurus) 24 kDa 0.00 %
90 Tubulin beta-5 chain (Bos taurus) 50 kDa 0.00 %
91 Keratin, type I cytoskeletal 17 (Homo sapiens) 48 kDa 0.00 %
92 26S protease regulatory subunit 7 (Bos taurus) 49 kDa 0.00 %
93 Creatine kinase B-type (Bos taurus) 43 kDa 0.00 %
94 40S ribosomal protein S13 (Bos taurus) 17 kDa 0.00 %
95 Dermcidin (Homo sapiens) 11 kDa 0.00 %
96 ADP-ribosylation factor-like protein 3 (Bos taurus) 21 kDa 0.00 %
97 Phosphoglycerate kinase 1 (Equus caballus) 45 kDa 0.00 %
98 Signal recognition particle 14 kDa protein (Pongo
abelii)
15 kDa 0.00 %
99 40S ribosomal protein SA (Bos taurus) 33 kDa 0.00 %
100 Electron transfer flavoprotein subunit beta (Mycobac-
terium bovis)
28 kDa 0.00 %
101 Ig kappa chain V-I region AG (Homo sapiens) 12 kDa 0.00 %
102 Mitotic spindle-associated MMXD complex subunit
MIP18 (Homo sapiens)
18 kDa 0.00 %
103 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4
(Bos taurus)
14 kDa 0.00 %
104 60S ribosomal protein L27a (Bos taurus) 17 kDa 0.00 %
105 Thioredoxin-1 (Escherichia coli) 12 kDa 0.00 %
106 Ubiquitin-conjugating enzyme E2 N (Bos taurus) 17 kDa 0.00 %
107 Vesicle-associated membrane protein 2 (Bos taurus) 13 kDa 0.00 %
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108 40S ribosomal protein S19 (Bos taurus) 16 kDa 0.00 %
109 NudC domain-containing protein 2 (Homo sapiens) 18 kDa 0.00 %
110 Proteasome subunit alpha type-2 (Bos taurus) 26 kDa 0.00 %
111 60S ribosomal protein L18a (Bos taurus) 21 kDa 0.00 %
112 Alpha-enolase (Homo sapiens) 47 kDa 0.00 %
113 Streptavidin-V1 (Streptomyces violaceus) 19 kDa 0.00 %
114 Thioredoxin (Homo sapiens) 12 kDa 0.00 %
115 Peroxiredoxin-2 (Cricetulus griseus) 22 kDa 0.00 %
116 60S ribosomal protein L23 (Bos taurus) 15 kDa 0.00 %
117 Protein Hikeshi (Bos taurus) 22 kDa 0.00 %
118 Splicing factor 3B subunit 3 (Bos taurus) 136 kDa 0.00 %
119 Eukaryotic translation initiation factor 1A, X-
chromosomal (Homo sapiens)
16 kDa 0.00 %
120 Cancer-related nucleoside-triphosphatase (Homo sapi-
ens)
21 kDa 0.00 %
121 Prefoldin subunit 2 (Bos taurus) 17 kDa 0.00 %
122 60S ribosomal protein L24 (Bos taurus) 18 kDa 0.00 %
123 60 kDa heat shock protein, mitochondrial (Bos taurus) 61 kDa 0.00 %
124 Prolactin-inducible protein (Homo sapiens) 17 kDa 0.00 %
125 Splicing factor 3B subunit 6 (Homo sapiens) 15 kDa 0.00 %
126 40S ribosomal protein S15a (Bos taurus) 15 kDa 0.00 %
127 General transcription factor IIH subunit 3 (Bos taurus) 34 kDa 0.00%
128 Clathrin light chain A (Bos taurus) 27 kDa 0.00 %
129 Heterogeneous nuclear ribonucleoprotein A1-like 2
(Homo sapiens)
34 kDa 0.00 %
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130 Four and a half LIM domains protein 1 (Homo sapiens) 36 kDa 0.00 %
131 Heterogeneous nuclear ribonucleoproteins A2/B1 (Bos
taurus)
36 kDa 0.00 %
132 40S ribosomal protein S23 (Bos taurus) 16 kDa 0.00 %
133 Cystatin-A (Homo sapiens) 11 kDa 0.00 %
134 Ferritin heavy chain (Canis familiaris) 21 kDa 0.00 %
Proteins < 0.01 % of total of spectra are labeled as 0.00 %.
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5.3 rAAV5 injection in the cochlea of mice
rAAV2/5-CAG-GFP
rAAV2/5-CaMKII-eNpHR3.0-eYFP
control injected
control injected
red = spiral ganglion neurons            
white = supporting cells 
100 µm
Figure 34: Expression of rAAV5 in the mouse cochlea rAAV2/5-CAG-GFP and
rAAV2/5-CaMKII-eNpHR3.0-eYFP were injected in the right cochleas of mice,
and the left uninjected cochleas served as controls. The cochleas were subsequently
stained against GFP. Relative GFP intensity was measurement by Fiji in refer-
ence areas, marked in red for spiral ganglion neurons and in white for supporting
cells. The injection of the mice and immunofluorescence staining was performed by
Vladan Rankovic and Daniela Gerke (University Medical Center, Göttingen), and
micrographs were taken together.
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5.4 The tetraspanin CD9 enhances exo-AAV production
anti-hAlix
anti-AAV
anti-CD63
anti-CD9
anti-GFP
20k x g 100k x g
M WT WTCD9 CD9 M rAAV1 M PEG
~100 kDa
~100 kDa
~60 kDa
~65 kDa
~40 kDa
~40 kDa
~20 kDa
Figure 35: Detection of exosomal markers, rAAVs, and GFP in vesicles of HEK-
AAV and HEK-AAV-CD9GFP cells 20k x g and 100k x g pellets of exo-AAV1
production in HEK-AAV and HEK-AAV-CD9GFP cells, standard rAAV1, and PEG
precipitated vesicles of HEK-AAV cells were precipitated with TCA. Western blot
detection of exosomal markers (hAlix, CD63, and CD9) confirmed abundance of
exosomes in 20k x g and 100k x g pellet and PEG precipitated vesicles. anti-
GFP detection confirmed expression of CD9GFP fusionprotein. M = Marker. The
experiment was partially performed by Nicolas Lemus (German Primate Center,
Göttingen). Creative commons license CC BY-NC-ND 4.0, modified from Schiller
et al. (2018).
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Figure 36: Transduction e ciency of media and 100k pellet of rAAV1 produced
in HEK-AAV and HEK-AAV-CD9GFP cells A serial dilution of exo-AAV1
media A-C and 100k pellet E,F produced in HEK-AAV and HEK-AAV-CD9GFP
cells were applied on HEK cells. The number of GFP transgene expressing cells
was evaluated 48h post transduction and the values plotted over the applied vector
genomes. Linear regression lines (red and blue) were fitted and the P-value (two-
tailed) calculated to test whether the slopes are significantly di erent. Error bars
indicate the standard deviation of technical triplicates. Creative commons license
CC BY-NC-ND 4.0, (Schiller et al., 2018).
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5.5 The tetraspanin CD9 enhances exosome secretion and lentivirus
infectivity
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Figure 37: The tetraspanin CD9 enhances exosome secretion and lentivirus infectiv-
ity (A) CD9 over-expression in HEK293, HEK293 FT, HeLa, Jurkat and Raji cells
was quantified by real-time PCR. (B-D) CD9 over-expression decreased the size of
PEG-precipitated vesicles, while it increased the vesicle and exosome amount.
(E) LV-VSVG and LV-VSVG-CD9 were applied on HEK293 cells with an MOI
range of 30-300 and the percentage of transgene expressing cells determined by flow
cytometry. (F) Density plot of flow cytometry analysis for HEK293 cells transduced
with an MOI of 150. Adapted with permissiom from Böker et al. (2017).
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